Details of the Drug Combinations

General Information of This Drug (ID: DM27D4J)

Drug Name
PD-0325901   DM27D4J
Synonyms
PD 0325901; PD 325901; PD0325901; PD325901; PD-325901; S06-0029; N-[((R)-2,3-dihydroxypropyl)oxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide; N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodo-phenyl)amino]benzamide; N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide
Indication
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Phase 2 [1]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1122 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
AXL-1717 + PD-0325901 DCWUDI9 AXL-1717 Hodgkin lymphoma (Cell Line: U-HO1) [2]
BIIB-021 + PD-0325901 DCYA6DX BIIB-021 Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [3]
BMS-754807 + PD-0325901 DC1H1JS BMS-754807 Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [3]
BMS-754807 + PD-0325901 DCS2CFH BMS-754807 Primitive neuroectodermal tumor (Cell Line: TC-32) [3]
CA4P + PD-0325901 DCTPSTS CA4P Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [3]
CUDC-101 + PD-0325901 DCXFTMV CUDC-101 Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [3]
CUDC-101 + PD-0325901 DCRCRD6 CUDC-101 Primitive neuroectodermal tumor (Cell Line: TC-32) [3]
Cyclophosphamide + PD-0325901 DC1XCHL Cyclophosphamide Adenocarcinoma (Cell Line: NCIH520) [3]
Cyclophosphamide + PD-0325901 DCUJZ4V Cyclophosphamide Adenocarcinoma (Cell Line: COLO320DM) [3]
Cyclophosphamide + PD-0325901 DCALC5U Cyclophosphamide Prostate carcinoma (Cell Line: VCAP) [3]
Cyclophosphamide + PD-0325901 DCZK2XQ Cyclophosphamide Breast carcinoma (Cell Line: KPL1) [4]
Cyclophosphamide + PD-0325901 DCMMSMM Cyclophosphamide Carcinoma (Cell Line: EFM192B) [4]
Cyclophosphamide + PD-0325901 DC7NZZJ Cyclophosphamide Invasive ductal carcinoma (Cell Line: T-47D) [4]
Dexamethasone + PD-0325901 DCNDT5T Dexamethasone Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Dexamethasone + PD-0325901 DCK992U Dexamethasone Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Dexamethasone + PD-0325901 DCD1NQR Dexamethasone Breast carcinoma (Cell Line: KPL1) [4]
Dexamethasone + PD-0325901 DCWCO3K Dexamethasone Carcinoma (Cell Line: EFM192B) [4]
Dexamethasone + PD-0325901 DCBP866 Dexamethasone Invasive ductal carcinoma (Cell Line: T-47D) [4]
Dexamethasone + PD-0325901 DCR0NRN Dexamethasone Adenocarcinoma (Cell Line: CAOV3) [2]
Dexamethasone + PD-0325901 DCLZROW Dexamethasone Adenocarcinoma (Cell Line: OVCAR3) [2]
Dexamethasone + PD-0325901 DCPDRHO Dexamethasone Adenocarcinoma (Cell Line: NCIH2122) [2]
Dexamethasone + PD-0325901 DC8NQEO Dexamethasone Adenocarcinoma (Cell Line: NCIH520) [2]
Dexamethasone + PD-0325901 DC7QVM9 Dexamethasone Adenocarcinoma (Cell Line: COLO320DM) [2]
Dexamethasone + PD-0325901 DCU5QH3 Dexamethasone Adenocarcinoma (Cell Line: DLD1) [2]
Dexamethasone + PD-0325901 DC5JZHB Dexamethasone Mesothelioma (Cell Line: MSTO) [2]
Dexamethasone + PD-0325901 DCLIQLP Dexamethasone Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
Dexamethasone + PD-0325901 DCF0VE2 Dexamethasone Prostate carcinoma (Cell Line: VCAP) [2]
Doxorubicin + PD-0325901 DC1PM0F Doxorubicin Adenocarcinoma (Cell Line: CAOV3) [3]
Doxorubicin + PD-0325901 DC3PZ1F Doxorubicin Adenocarcinoma (Cell Line: OVCAR3) [3]
Doxorubicin + PD-0325901 DC776LG Doxorubicin Adenocarcinoma (Cell Line: NCIH1650) [3]
Doxorubicin + PD-0325901 DCL5V9Y Doxorubicin Adenocarcinoma (Cell Line: NCIH2122) [3]
Doxorubicin + PD-0325901 DCP8ODG Doxorubicin Adenocarcinoma (Cell Line: NCIH23) [3]
Doxorubicin + PD-0325901 DCB7B5H Doxorubicin Adenocarcinoma (Cell Line: NCIH520) [3]
Doxorubicin + PD-0325901 DCRMVUE Doxorubicin Adenocarcinoma (Cell Line: COLO320DM) [3]
Doxorubicin + PD-0325901 DCA1USD Doxorubicin Adenocarcinoma (Cell Line: HT29) [3]
Doxorubicin + PD-0325901 DC2FWXV Doxorubicin Adenocarcinoma (Cell Line: SW-620) [3]
Doxorubicin + PD-0325901 DCI14QR Doxorubicin Adenocarcinoma (Cell Line: HCT116) [3]
Doxorubicin + PD-0325901 DC0YQVQ Doxorubicin Amelanotic melanoma (Cell Line: A2058) [3]
Doxorubicin + PD-0325901 DCLHCEX Doxorubicin Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Doxorubicin + PD-0325901 DC5047B Doxorubicin Germ cell tumour (Cell Line: PA1) [3]
Doxorubicin + PD-0325901 DCX5UAT Doxorubicin Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Doxorubicin + PD-0325901 DCAW1EH Doxorubicin Malignant melanoma (Cell Line: A375) [3]
Doxorubicin + PD-0325901 DCWRKUL Doxorubicin Malignant melanoma (Cell Line: HT144) [3]
Doxorubicin + PD-0325901 DCSXNQO Doxorubicin Malignant melanoma (Cell Line: RPMI7951) [3]
Doxorubicin + PD-0325901 DCZ4TO4 Doxorubicin Malignant melanoma (Cell Line: SKMEL30) [3]
Doxorubicin + PD-0325901 DC24OIX Doxorubicin Mesothelioma (Cell Line: MSTO) [3]
Doxorubicin + PD-0325901 DCGH6XJ Doxorubicin Non small cell carcinoma (Cell Line: SKMES1) [3]
Doxorubicin + PD-0325901 DCUQ7IG Doxorubicin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Doxorubicin + PD-0325901 DCV5W2P Doxorubicin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Doxorubicin + PD-0325901 DC4RR43 Doxorubicin Prostate carcinoma (Cell Line: LNCAP) [3]
Doxorubicin + PD-0325901 DCS45KD Doxorubicin Prostate carcinoma (Cell Line: VCAP) [3]
Doxorubicin + PD-0325901 DCV7V4A Doxorubicin Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Doxorubicin + PD-0325901 DCX196W Doxorubicin Breast carcinoma (Cell Line: OCUBM) [4]
Doxorubicin + PD-0325901 DCMVPVF Doxorubicin Carcinoma (Cell Line: EFM192B) [4]
Doxorubicin + PD-0325901 DC5RDA5 Doxorubicin Colon adenocarcinoma (Cell Line: LOVO) [4]
Doxorubicin + PD-0325901 DCE0ETS Doxorubicin Colon carcinoma (Cell Line: RKO) [4]
Doxorubicin + PD-0325901 DCB7OEP Doxorubicin Invasive ductal carcinoma (Cell Line: T-47D) [4]
Doxorubicin + PD-0325901 DC74XPA Doxorubicin Rectal adenocarcinoma (Cell Line: SW837) [4]
Erlotinib + PD-0325901 DCFF73B Erlotinib Adenocarcinoma (Cell Line: CAOV3) [3]
Erlotinib + PD-0325901 DCOAHGV Erlotinib Adenocarcinoma (Cell Line: NCIH1650) [3]
Erlotinib + PD-0325901 DCQD2J4 Erlotinib Adenocarcinoma (Cell Line: NCIH2122) [3]
Erlotinib + PD-0325901 DCNO82O Erlotinib Adenocarcinoma (Cell Line: COLO320DM) [3]
Erlotinib + PD-0325901 DCHA3MV Erlotinib Adenocarcinoma (Cell Line: DLD1) [3]
Erlotinib + PD-0325901 DCZNCV2 Erlotinib Amelanotic melanoma (Cell Line: A2058) [3]
Erlotinib + PD-0325901 DCMEZXS Erlotinib Germ cell tumour (Cell Line: PA1) [3]
Erlotinib + PD-0325901 DC7AYRW Erlotinib Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Erlotinib + PD-0325901 DCA2WUE Erlotinib Malignant melanoma (Cell Line: A375) [3]
Erlotinib + PD-0325901 DCSVYUE Erlotinib Malignant melanoma (Cell Line: HT144) [3]
Erlotinib + PD-0325901 DCXRKRI Erlotinib Malignant melanoma (Cell Line: SKMEL30) [3]
Erlotinib + PD-0325901 DCV2YIR Erlotinib Malignant melanoma (Cell Line: UACC62) [3]
Erlotinib + PD-0325901 DCM2YFH Erlotinib Mesothelioma (Cell Line: MSTO) [3]
Erlotinib + PD-0325901 DCRJZCE Erlotinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Erlotinib + PD-0325901 DC1GOLX Erlotinib Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Erlotinib + PD-0325901 DC8IMPR Erlotinib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Erlotinib + PD-0325901 DCBPRBC Erlotinib Carcinoma (Cell Line: OV90) [4]
Erlotinib + PD-0325901 DCG00WC Erlotinib Carcinoma (Cell Line: EFM192B) [4]
Erlotinib + PD-0325901 DCB04C9 Erlotinib Invasive ductal carcinoma (Cell Line: T-47D) [4]
Estramustine + PD-0325901 DCD5TK4 Estramustine Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Estramustine + PD-0325901 DC4ME60 Estramustine Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Estramustine + PD-0325901 DC1M5U6 Estramustine Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Estramustine + PD-0325901 DC9Y4P6 Estramustine Breast carcinoma (Cell Line: KPL1) [4]
Estramustine + PD-0325901 DCP63WV Estramustine Breast carcinoma (Cell Line: OCUBM) [4]
Estramustine + PD-0325901 DCOY2BX Estramustine Carcinoma (Cell Line: EFM192B) [4]
Estramustine + PD-0325901 DCG4CYY Estramustine Carcinoma (Cell Line: MDAMB436) [4]
Estramustine + PD-0325901 DC3V8OT Estramustine Invasive ductal carcinoma (Cell Line: T-47D) [4]
Estramustine + PD-0325901 DC0545T Estramustine Adenocarcinoma (Cell Line: CAOV3) [2]
Estramustine + PD-0325901 DCQ9F0P Estramustine Adenocarcinoma (Cell Line: OVCAR3) [2]
Estramustine + PD-0325901 DCYDEED Estramustine Adenocarcinoma (Cell Line: A427) [2]
Estramustine + PD-0325901 DCSQQVH Estramustine Adenocarcinoma (Cell Line: NCIH2122) [2]
Estramustine + PD-0325901 DC44G0T Estramustine Adenocarcinoma (Cell Line: NCIH23) [2]
Estramustine + PD-0325901 DCFRU69 Estramustine Adenocarcinoma (Cell Line: NCIH520) [2]
Estramustine + PD-0325901 DC58FB5 Estramustine Adenocarcinoma (Cell Line: COLO320DM) [2]
Estramustine + PD-0325901 DCPPMJ9 Estramustine Adenocarcinoma (Cell Line: DLD1) [2]
Estramustine + PD-0325901 DC81XCM Estramustine Adenocarcinoma (Cell Line: HT29) [2]
Estramustine + PD-0325901 DCTSPB4 Estramustine Amelanotic melanoma (Cell Line: A2058) [2]
Estramustine + PD-0325901 DCKZ09N Estramustine Germ cell tumour (Cell Line: PA1) [2]
Estramustine + PD-0325901 DCIT9L4 Estramustine Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Estramustine + PD-0325901 DCZ9WJC Estramustine Malignant melanoma (Cell Line: A375) [2]
Estramustine + PD-0325901 DCV1I7W Estramustine Malignant melanoma (Cell Line: HT144) [2]
Estramustine + PD-0325901 DC95CGP Estramustine Malignant melanoma (Cell Line: RPMI7951) [2]
Estramustine + PD-0325901 DC14T11 Estramustine Malignant melanoma (Cell Line: SKMEL30) [2]
Estramustine + PD-0325901 DC13469 Estramustine Malignant melanoma (Cell Line: UACC62) [2]
Estramustine + PD-0325901 DCHHF1E Estramustine Mesothelioma (Cell Line: MSTO) [2]
Estramustine + PD-0325901 DC51QDF Estramustine Non small cell carcinoma (Cell Line: SKMES1) [2]
Estramustine + PD-0325901 DCCIIBJ Estramustine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [2]
Estramustine + PD-0325901 DC2OOVD Estramustine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
Estramustine + PD-0325901 DC68JS8 Estramustine Prostate carcinoma (Cell Line: VCAP) [2]
Etoposide + PD-0325901 DCFW7M0 Etoposide Adenocarcinoma (Cell Line: CAOV3) [3]
Etoposide + PD-0325901 DCXEMK1 Etoposide Adenocarcinoma (Cell Line: NCIH1650) [3]
Etoposide + PD-0325901 DCAQBON Etoposide Adenocarcinoma (Cell Line: NCIH2122) [3]
Etoposide + PD-0325901 DCNUD3H Etoposide Adenocarcinoma (Cell Line: NCIH520) [3]
Etoposide + PD-0325901 DCAU6Z7 Etoposide Adenocarcinoma (Cell Line: COLO320DM) [3]
Etoposide + PD-0325901 DCOF1EO Etoposide Adenocarcinoma (Cell Line: DLD1) [3]
Etoposide + PD-0325901 DC84ILQ Etoposide Adenocarcinoma (Cell Line: HCT116) [3]
Etoposide + PD-0325901 DC2TKG0 Etoposide Adenocarcinoma (Cell Line: HT29) [3]
Etoposide + PD-0325901 DCUBUR7 Etoposide Amelanotic melanoma (Cell Line: A2058) [3]
Etoposide + PD-0325901 DC4NRYF Etoposide Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Etoposide + PD-0325901 DC7CP0F Etoposide Germ cell tumour (Cell Line: PA1) [3]
Etoposide + PD-0325901 DC2ZWZ3 Etoposide Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Etoposide + PD-0325901 DCBXS1W Etoposide Malignant melanoma (Cell Line: A375) [3]
Etoposide + PD-0325901 DC8HEMC Etoposide Malignant melanoma (Cell Line: HT144) [3]
Etoposide + PD-0325901 DC72OJJ Etoposide Malignant melanoma (Cell Line: RPMI7951) [3]
Etoposide + PD-0325901 DCF6WNH Etoposide Malignant melanoma (Cell Line: SKMEL30) [3]
Etoposide + PD-0325901 DCTCPIB Etoposide Malignant melanoma (Cell Line: UACC62) [3]
Etoposide + PD-0325901 DCWM0RI Etoposide Mesothelioma (Cell Line: MSTO) [3]
Etoposide + PD-0325901 DCSTDWN Etoposide Non small cell carcinoma (Cell Line: SKMES1) [3]
Etoposide + PD-0325901 DCQUX7Z Etoposide Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Etoposide + PD-0325901 DCNE4SX Etoposide Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Etoposide + PD-0325901 DCYVZVV Etoposide Prostate carcinoma (Cell Line: LNCAP) [3]
Etoposide + PD-0325901 DC3X626 Etoposide Prostate carcinoma (Cell Line: VCAP) [3]
Etoposide + PD-0325901 DC0JL94 Etoposide Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Etoposide + PD-0325901 DCP2BVK Etoposide Breast carcinoma (Cell Line: ZR751) [4]
Etoposide + PD-0325901 DCYBN4X Etoposide Breast carcinoma (Cell Line: KPL1) [4]
Etoposide + PD-0325901 DCIBB8E Etoposide Breast carcinoma (Cell Line: OCUBM) [4]
Etoposide + PD-0325901 DCVOVFB Etoposide Carcinoma (Cell Line: OV90) [4]
Etoposide + PD-0325901 DCNU553 Etoposide Carcinoma (Cell Line: EFM192B) [4]
Etoposide + PD-0325901 DCF1W5I Etoposide Carcinoma (Cell Line: MDAMB436) [4]
Etoposide + PD-0325901 DCXCY8S Etoposide Colon carcinoma (Cell Line: RKO) [4]
Etoposide + PD-0325901 DC9XTLY Etoposide Invasive ductal carcinoma (Cell Line: T-47D) [4]
Etoposide + PD-0325901 DCANEJ9 Etoposide Rectal adenocarcinoma (Cell Line: SW837) [4]
Fluorouracil + PD-0325901 DC4XUHV Fluorouracil Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Fluorouracil + PD-0325901 DC7HONE Fluorouracil Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Fluorouracil + PD-0325901 DC5X7DL Fluorouracil Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Fluorouracil + PD-0325901 DCZBRAF Fluorouracil Breast carcinoma (Cell Line: KPL1) [4]
Fluorouracil + PD-0325901 DCDZFYY Fluorouracil Breast carcinoma (Cell Line: OCUBM) [4]
Fluorouracil + PD-0325901 DCBAAWV Fluorouracil Carcinoma (Cell Line: OV90) [4]
Fluorouracil + PD-0325901 DCGQHNK Fluorouracil Carcinoma (Cell Line: EFM192B) [4]
Fluorouracil + PD-0325901 DC22TXQ Fluorouracil Carcinoma (Cell Line: MDAMB436) [4]
Fluorouracil + PD-0325901 DCTG9JF Fluorouracil Colon adenocarcinoma (Cell Line: LOVO) [4]
Fluorouracil + PD-0325901 DC91D7D Fluorouracil Colon carcinoma (Cell Line: RKO) [4]
Fluorouracil + PD-0325901 DCK7CYM Fluorouracil Invasive ductal carcinoma (Cell Line: T-47D) [4]
Fluorouracil + PD-0325901 DCA2TH2 Fluorouracil Adenocarcinoma (Cell Line: CAOV3) [2]
Fluorouracil + PD-0325901 DCRMWFV Fluorouracil Adenocarcinoma (Cell Line: OVCAR3) [2]
Fluorouracil + PD-0325901 DCIO4WY Fluorouracil Adenocarcinoma (Cell Line: A427) [2]
Fluorouracil + PD-0325901 DC4TJW5 Fluorouracil Adenocarcinoma (Cell Line: NCIH1650) [2]
Fluorouracil + PD-0325901 DCOJJMV Fluorouracil Adenocarcinoma (Cell Line: NCIH2122) [2]
Fluorouracil + PD-0325901 DCIII14 Fluorouracil Adenocarcinoma (Cell Line: NCIH23) [2]
Fluorouracil + PD-0325901 DC04YQK Fluorouracil Adenocarcinoma (Cell Line: NCIH520) [2]
Fluorouracil + PD-0325901 DCTJ9L3 Fluorouracil Adenocarcinoma (Cell Line: COLO320DM) [2]
Fluorouracil + PD-0325901 DCJYHPK Fluorouracil Adenocarcinoma (Cell Line: DLD1) [2]
Fluorouracil + PD-0325901 DC7RGZA Fluorouracil Adenocarcinoma (Cell Line: HCT116) [2]
Fluorouracil + PD-0325901 DCCPCYU Fluorouracil Adenocarcinoma (Cell Line: HT29) [2]
Fluorouracil + PD-0325901 DCL1UMP Fluorouracil Germ cell tumour (Cell Line: PA1) [2]
Fluorouracil + PD-0325901 DCOM8WN Fluorouracil Malignant melanoma (Cell Line: A375) [2]
Fluorouracil + PD-0325901 DCJVOG0 Fluorouracil Malignant melanoma (Cell Line: RPMI7951) [2]
Fluorouracil + PD-0325901 DCNEQ35 Fluorouracil Malignant melanoma (Cell Line: SKMEL30) [2]
Fluorouracil + PD-0325901 DCURTXP Fluorouracil Malignant melanoma (Cell Line: UACC62) [2]
Fluorouracil + PD-0325901 DCVCSVJ Fluorouracil Mesothelioma (Cell Line: MSTO) [2]
Fluorouracil + PD-0325901 DC7T3FD Fluorouracil Non small cell carcinoma (Cell Line: SKMES1) [2]
Fluorouracil + PD-0325901 DCWCK5H Fluorouracil Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [2]
Fluorouracil + PD-0325901 DCWJ31F Fluorouracil Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
Fluorouracil + PD-0325901 DCTKYQJ Fluorouracil Prostate carcinoma (Cell Line: VCAP) [2]
Fluorouracil + PD-0325901 DCEDZFB Fluorouracil Prostate carcinoma (Cell Line: LNCAP) [2]
GDC-0980/RG7422 + PD-0325901 DCZJMSK GDC-0980/RG7422 Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [3]
Gemcitabine + PD-0325901 DC8IYM5 Gemcitabine Adenocarcinoma (Cell Line: CAOV3) [3]
Gemcitabine + PD-0325901 DCERP08 Gemcitabine Adenocarcinoma (Cell Line: OVCAR3) [3]
Gemcitabine + PD-0325901 DC06QZF Gemcitabine Adenocarcinoma (Cell Line: A427) [3]
Gemcitabine + PD-0325901 DCD4O3Y Gemcitabine Adenocarcinoma (Cell Line: NCIH1650) [3]
Gemcitabine + PD-0325901 DCAKIQH Gemcitabine Adenocarcinoma (Cell Line: NCIH2122) [3]
Gemcitabine + PD-0325901 DCOEZF7 Gemcitabine Adenocarcinoma (Cell Line: NCIH23) [3]
Gemcitabine + PD-0325901 DCA5QDO Gemcitabine Adenocarcinoma (Cell Line: NCIH520) [3]
Gemcitabine + PD-0325901 DC6HX4S Gemcitabine Adenocarcinoma (Cell Line: COLO320DM) [3]
Gemcitabine + PD-0325901 DCMTFK2 Gemcitabine Adenocarcinoma (Cell Line: DLD1) [3]
Gemcitabine + PD-0325901 DCPFL52 Gemcitabine Adenocarcinoma (Cell Line: HCT116) [3]
Gemcitabine + PD-0325901 DC4QGK2 Gemcitabine Adenocarcinoma (Cell Line: HT29) [3]
Gemcitabine + PD-0325901 DCBRYAF Gemcitabine Adenocarcinoma (Cell Line: SW-620) [3]
Gemcitabine + PD-0325901 DC1VG1L Gemcitabine Amelanotic melanoma (Cell Line: A2058) [3]
Gemcitabine + PD-0325901 DCK5EPB Gemcitabine Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Gemcitabine + PD-0325901 DCS1YO6 Gemcitabine Germ cell tumour (Cell Line: PA1) [3]
Gemcitabine + PD-0325901 DCSZ5YI Gemcitabine Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Gemcitabine + PD-0325901 DCNLK8Z Gemcitabine Malignant melanoma (Cell Line: HT144) [3]
Gemcitabine + PD-0325901 DCN0PBY Gemcitabine Malignant melanoma (Cell Line: RPMI7951) [3]
Gemcitabine + PD-0325901 DCPY9O3 Gemcitabine Malignant melanoma (Cell Line: SKMEL30) [3]
Gemcitabine + PD-0325901 DCUQFUZ Gemcitabine Malignant melanoma (Cell Line: UACC62) [3]
Gemcitabine + PD-0325901 DC6DEPA Gemcitabine Malignant melanoma (Cell Line: A375) [3]
Gemcitabine + PD-0325901 DC96ZT4 Gemcitabine Mesothelioma (Cell Line: MSTO) [3]
Gemcitabine + PD-0325901 DCMGWJY Gemcitabine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Gemcitabine + PD-0325901 DCX2USE Gemcitabine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Gemcitabine + PD-0325901 DCU7I8B Gemcitabine Prostate carcinoma (Cell Line: LNCAP) [3]
Gemcitabine + PD-0325901 DC0PV2N Gemcitabine Prostate carcinoma (Cell Line: VCAP) [3]
Gemcitabine + PD-0325901 DCK4MOL Gemcitabine Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Gemcitabine + PD-0325901 DCE2GMW Gemcitabine Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Gemcitabine + PD-0325901 DCN8J7R Gemcitabine Breast carcinoma (Cell Line: KPL1) [4]
Gemcitabine + PD-0325901 DCK39BP Gemcitabine Breast carcinoma (Cell Line: OCUBM) [4]
Gemcitabine + PD-0325901 DCK8FDZ Gemcitabine Carcinoma (Cell Line: OV90) [4]
Gemcitabine + PD-0325901 DC4C9RD Gemcitabine Carcinoma (Cell Line: EFM192B) [4]
Gemcitabine + PD-0325901 DCBMUKR Gemcitabine Carcinoma (Cell Line: MDAMB436) [4]
Gemcitabine + PD-0325901 DC7ZVP8 Gemcitabine Colon carcinoma (Cell Line: RKO) [4]
Gemcitabine + PD-0325901 DCVVQP7 Gemcitabine Invasive ductal carcinoma (Cell Line: T-47D) [4]
Gemcitabine + PD-0325901 DC0VRBS Gemcitabine Rectal adenocarcinoma (Cell Line: SW837) [4]
GSK618334 + PD-0325901 DC4SC6P GSK618334 Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [3]
Idarubicin + PD-0325901 DCK3QO8 Idarubicin Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Idarubicin + PD-0325901 DC846KO Idarubicin Breast carcinoma (Cell Line: KPL1) [4]
Idarubicin + PD-0325901 DCYIHJS Idarubicin Breast carcinoma (Cell Line: OCUBM) [4]
Idarubicin + PD-0325901 DCGW9EH Idarubicin Carcinoma (Cell Line: OV90) [4]
Idarubicin + PD-0325901 DC02R95 Idarubicin Carcinoma (Cell Line: EFM192B) [4]
Idarubicin + PD-0325901 DCMZH25 Idarubicin Carcinoma (Cell Line: MDAMB436) [4]
Idarubicin + PD-0325901 DCC2Y0H Idarubicin Invasive ductal carcinoma (Cell Line: T-47D) [4]
Idarubicin + PD-0325901 DCIWIFF Idarubicin Adenocarcinoma (Cell Line: A427) [2]
Idarubicin + PD-0325901 DCRFJ4E Idarubicin Adenocarcinoma (Cell Line: NCIH2122) [2]
Idarubicin + PD-0325901 DC5KHUQ Idarubicin Adenocarcinoma (Cell Line: NCIH23) [2]
Idarubicin + PD-0325901 DC36ADM Idarubicin Adenocarcinoma (Cell Line: NCIH520) [2]
Idarubicin + PD-0325901 DCXGARB Idarubicin Adenocarcinoma (Cell Line: COLO320DM) [2]
Idarubicin + PD-0325901 DC036XS Idarubicin Adenocarcinoma (Cell Line: DLD1) [2]
Idarubicin + PD-0325901 DCT3VG4 Idarubicin Amelanotic melanoma (Cell Line: A2058) [2]
Idarubicin + PD-0325901 DCK7L3P Idarubicin Germ cell tumour (Cell Line: PA1) [2]
Idarubicin + PD-0325901 DC5MMFN Idarubicin Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Idarubicin + PD-0325901 DC4YD0T Idarubicin Malignant melanoma (Cell Line: A375) [2]
Idarubicin + PD-0325901 DCS2G1Q Idarubicin Malignant melanoma (Cell Line: RPMI7951) [2]
Idarubicin + PD-0325901 DC0SIR0 Idarubicin Malignant melanoma (Cell Line: UACC62) [2]
Idarubicin + PD-0325901 DCH8R8G Idarubicin Mesothelioma (Cell Line: MSTO) [2]
Idarubicin + PD-0325901 DC52CUG Idarubicin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [2]
Lapatinib + PD-0325901 DCN0E7E Lapatinib Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Lapatinib + PD-0325901 DCL98IZ Lapatinib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Lapatinib + PD-0325901 DCZY7TD Lapatinib Breast carcinoma (Cell Line: ZR751) [4]
Lapatinib + PD-0325901 DC909I2 Lapatinib Breast carcinoma (Cell Line: KPL1) [4]
Lapatinib + PD-0325901 DCBGYAK Lapatinib Breast carcinoma (Cell Line: OCUBM) [4]
Lapatinib + PD-0325901 DCGP215 Lapatinib Carcinoma (Cell Line: OV90) [4]
Lapatinib + PD-0325901 DCK8EQV Lapatinib Carcinoma (Cell Line: EFM192B) [4]
Lapatinib + PD-0325901 DCMEXFB Lapatinib Carcinoma (Cell Line: MDAMB436) [4]
Lapatinib + PD-0325901 DCJSORG Lapatinib Colon adenocarcinoma (Cell Line: LOVO) [4]
Lapatinib + PD-0325901 DCJ5A6D Lapatinib Colon carcinoma (Cell Line: RKO) [4]
Lapatinib + PD-0325901 DCJ3U73 Lapatinib Invasive ductal carcinoma (Cell Line: T-47D) [4]
Lapatinib + PD-0325901 DCUCGP5 Lapatinib Rectal adenocarcinoma (Cell Line: SW837) [4]
Lapatinib + PD-0325901 DCJLIXT Lapatinib Adenocarcinoma (Cell Line: CAOV3) [2]
Lapatinib + PD-0325901 DCQDUXE Lapatinib Adenocarcinoma (Cell Line: OVCAR3) [2]
Lapatinib + PD-0325901 DCI4N4J Lapatinib Adenocarcinoma (Cell Line: A427) [2]
Lapatinib + PD-0325901 DCN9156 Lapatinib Adenocarcinoma (Cell Line: NCIH1650) [2]
Lapatinib + PD-0325901 DC7Q9B6 Lapatinib Adenocarcinoma (Cell Line: NCIH2122) [2]
Lapatinib + PD-0325901 DCWPX30 Lapatinib Adenocarcinoma (Cell Line: NCIH23) [2]
Lapatinib + PD-0325901 DC078BX Lapatinib Adenocarcinoma (Cell Line: NCIH520) [2]
Lapatinib + PD-0325901 DCQMU7N Lapatinib Adenocarcinoma (Cell Line: COLO320DM) [2]
Lapatinib + PD-0325901 DCWGBCD Lapatinib Adenocarcinoma (Cell Line: DLD1) [2]
Lapatinib + PD-0325901 DCHBSZJ Lapatinib Adenocarcinoma (Cell Line: HT29) [2]
Lapatinib + PD-0325901 DC5OTT4 Lapatinib Amelanotic melanoma (Cell Line: A2058) [2]
Lapatinib + PD-0325901 DCO4MNH Lapatinib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [2]
Lapatinib + PD-0325901 DCZ9V28 Lapatinib Germ cell tumour (Cell Line: PA1) [2]
Lapatinib + PD-0325901 DCGNIMN Lapatinib Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Lapatinib + PD-0325901 DCGTD23 Lapatinib Malignant melanoma (Cell Line: HT144) [2]
Lapatinib + PD-0325901 DCS4RNP Lapatinib Malignant melanoma (Cell Line: RPMI7951) [2]
Lapatinib + PD-0325901 DCFVMNF Lapatinib Malignant melanoma (Cell Line: UACC62) [2]
Lapatinib + PD-0325901 DCSAETK Lapatinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [2]
Lapatinib + PD-0325901 DC0YFC7 Lapatinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
Lapatinib + PD-0325901 DCAII4H Lapatinib Prostate carcinoma (Cell Line: LNCAP) [2]
Lapatinib + PD-0325901 DCMOFZ7 Lapatinib Prostate carcinoma (Cell Line: VCAP) [2]
Metformin + PD-0325901 DCP2IQW Metformin Adenocarcinoma (Cell Line: CAOV3) [3]
Metformin + PD-0325901 DC4Z6O0 Metformin Adenocarcinoma (Cell Line: OVCAR3) [3]
Metformin + PD-0325901 DCXB88W Metformin Adenocarcinoma (Cell Line: NCIH2122) [3]
Metformin + PD-0325901 DCZ6PF2 Metformin Adenocarcinoma (Cell Line: NCIH520) [3]
Metformin + PD-0325901 DCDA23D Metformin Adenocarcinoma (Cell Line: COLO320DM) [3]
Metformin + PD-0325901 DC0WLO5 Metformin Adenocarcinoma (Cell Line: DLD1) [3]
Metformin + PD-0325901 DCABTUY Metformin Adenocarcinoma (Cell Line: HT29) [3]
Metformin + PD-0325901 DCQO4R7 Metformin Amelanotic melanoma (Cell Line: A2058) [3]
Metformin + PD-0325901 DCFGBHV Metformin Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Metformin + PD-0325901 DC0GG3I Metformin Germ cell tumour (Cell Line: PA1) [3]
Metformin + PD-0325901 DCR0WZX Metformin Malignant melanoma (Cell Line: HT144) [3]
Metformin + PD-0325901 DC3M1J1 Metformin Malignant melanoma (Cell Line: SKMEL30) [3]
Metformin + PD-0325901 DCBBVT2 Metformin Malignant melanoma (Cell Line: UACC62) [3]
Metformin + PD-0325901 DCG259W Metformin Mesothelioma (Cell Line: MSTO) [3]
Metformin + PD-0325901 DCNBUPU Metformin Non small cell carcinoma (Cell Line: SKMES1) [3]
Metformin + PD-0325901 DCWKVP3 Metformin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Metformin + PD-0325901 DCSJBBW Metformin Prostate carcinoma (Cell Line: LNCAP) [3]
Metformin + PD-0325901 DCSC265 Metformin Prostate carcinoma (Cell Line: VCAP) [3]
Metformin + PD-0325901 DCOK0MR Metformin Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Metformin + PD-0325901 DCEGQNG Metformin Breast carcinoma (Cell Line: KPL1) [4]
Metformin + PD-0325901 DC2CL7X Metformin Breast carcinoma (Cell Line: OCUBM) [4]
Metformin + PD-0325901 DC9DG9K Metformin Carcinoma (Cell Line: EFM192B) [4]
Metformin + PD-0325901 DC28IMT Metformin Invasive ductal carcinoma (Cell Line: T-47D) [4]
Methotrexate + PD-0325901 DCNIQOH Methotrexate Adenocarcinoma (Cell Line: OVCAR3) [3]
Methotrexate + PD-0325901 DCO0NF3 Methotrexate Adenocarcinoma (Cell Line: NCIH1650) [3]
Methotrexate + PD-0325901 DCMJV0L Methotrexate Adenocarcinoma (Cell Line: NCIH23) [3]
Methotrexate + PD-0325901 DC6SBDF Methotrexate Germ cell tumour (Cell Line: PA1) [3]
Methotrexate + PD-0325901 DCFGZ9L Methotrexate Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Methotrexate + PD-0325901 DCQY2DZ Methotrexate Malignant melanoma (Cell Line: HT144) [3]
Methotrexate + PD-0325901 DC293HJ Methotrexate Malignant melanoma (Cell Line: RPMI7951) [3]
Methotrexate + PD-0325901 DC4E89G Methotrexate Malignant melanoma (Cell Line: SKMEL30) [3]
Methotrexate + PD-0325901 DC5112T Methotrexate Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Methotrexate + PD-0325901 DCB63BB Methotrexate Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Methotrexate + PD-0325901 DC2ZK87 Methotrexate Breast carcinoma (Cell Line: KPL1) [4]
Methotrexate + PD-0325901 DCWPOB5 Methotrexate Carcinoma (Cell Line: EFM192B) [4]
Methotrexate + PD-0325901 DCXJNA2 Methotrexate Rectal adenocarcinoma (Cell Line: SW837) [4]
Mitomycin + PD-0325901 DCV4WI9 Mitomycin Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Mitomycin + PD-0325901 DCRF46C Mitomycin Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Mitomycin + PD-0325901 DCV7GWW Mitomycin Breast carcinoma (Cell Line: KPL1) [4]
Mitomycin + PD-0325901 DCB0N4P Mitomycin Breast carcinoma (Cell Line: OCUBM) [4]
Mitomycin + PD-0325901 DCVWRZZ Mitomycin Carcinoma (Cell Line: OV90) [4]
Mitomycin + PD-0325901 DC406B7 Mitomycin Carcinoma (Cell Line: EFM192B) [4]
Mitomycin + PD-0325901 DC0ZYZJ Mitomycin Carcinoma (Cell Line: MDAMB436) [4]
Mitomycin + PD-0325901 DCYCXYP Mitomycin Colon adenocarcinoma (Cell Line: LOVO) [4]
Mitomycin + PD-0325901 DCFJ2HS Mitomycin Colon carcinoma (Cell Line: RKO) [4]
Mitomycin + PD-0325901 DCPH4KH Mitomycin Invasive ductal carcinoma (Cell Line: T-47D) [4]
Mitomycin + PD-0325901 DCAJIB6 Mitomycin Rectal adenocarcinoma (Cell Line: SW837) [4]
Mitomycin + PD-0325901 DCD5H77 Mitomycin Adenocarcinoma (Cell Line: CAOV3) [2]
Mitomycin + PD-0325901 DCSZC0X Mitomycin Adenocarcinoma (Cell Line: OVCAR3) [2]
Mitomycin + PD-0325901 DCIHP4O Mitomycin Adenocarcinoma (Cell Line: A427) [2]
Mitomycin + PD-0325901 DCITH2O Mitomycin Adenocarcinoma (Cell Line: NCIH1650) [2]
Mitomycin + PD-0325901 DCIP9QH Mitomycin Adenocarcinoma (Cell Line: NCIH2122) [2]
Mitomycin + PD-0325901 DCIM1KN Mitomycin Adenocarcinoma (Cell Line: NCIH23) [2]
Mitomycin + PD-0325901 DCJC6U8 Mitomycin Adenocarcinoma (Cell Line: NCIH520) [2]
Mitomycin + PD-0325901 DCK5UUF Mitomycin Adenocarcinoma (Cell Line: COLO320DM) [2]
Mitomycin + PD-0325901 DC8YUWU Mitomycin Adenocarcinoma (Cell Line: DLD1) [2]
Mitomycin + PD-0325901 DC377VW Mitomycin Adenocarcinoma (Cell Line: HCT116) [2]
Mitomycin + PD-0325901 DCQEL2Y Mitomycin Adenocarcinoma (Cell Line: HT29) [2]
Mitomycin + PD-0325901 DCKZZVJ Mitomycin Adenocarcinoma (Cell Line: SW-620) [2]
Mitomycin + PD-0325901 DC7GN09 Mitomycin Amelanotic melanoma (Cell Line: A2058) [2]
Mitomycin + PD-0325901 DCBEYEA Mitomycin Germ cell tumour (Cell Line: PA1) [2]
Mitomycin + PD-0325901 DCSW3WB Mitomycin Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Mitomycin + PD-0325901 DC7PHVP Mitomycin Malignant melanoma (Cell Line: A375) [2]
Mitomycin + PD-0325901 DCHLMJ3 Mitomycin Malignant melanoma (Cell Line: HT144) [2]
Mitomycin + PD-0325901 DCG5M1V Mitomycin Malignant melanoma (Cell Line: RPMI7951) [2]
Mitomycin + PD-0325901 DCI10O3 Mitomycin Malignant melanoma (Cell Line: SKMEL30) [2]
Mitomycin + PD-0325901 DC6Q4J1 Mitomycin Malignant melanoma (Cell Line: UACC62) [2]
Mitomycin + PD-0325901 DCM91WH Mitomycin Mesothelioma (Cell Line: MSTO) [2]
Mitomycin + PD-0325901 DCKJNM7 Mitomycin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [2]
Mitomycin + PD-0325901 DCTT5FO Mitomycin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
Mitomycin + PD-0325901 DCFBTOF Mitomycin Prostate carcinoma (Cell Line: VCAP) [2]
MK-1775 + PD-0325901 DCE76BJ MK-1775 Adenocarcinoma (Cell Line: CAOV3) [3]
MK-1775 + PD-0325901 DCSX6QD MK-1775 Adenocarcinoma (Cell Line: NCIH2122) [3]
MK-1775 + PD-0325901 DCXYLII MK-1775 Adenocarcinoma (Cell Line: DLD1) [3]
MK-1775 + PD-0325901 DC1558R MK-1775 Hodgkin lymphoma (Cell Line: U-HO1) [3]
MK-1775 + PD-0325901 DCFOLRX MK-1775 Mesothelioma (Cell Line: MSTO) [3]
MK-1775 + PD-0325901 DCUUTTR MK-1775 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
MK-1775 + PD-0325901 DCDYWYN MK-1775 Prostate carcinoma (Cell Line: VCAP) [3]
MK-1775 + PD-0325901 DCJNFVQ MK-1775 Breast carcinoma (Cell Line: OCUBM) [4]
MK-1775 + PD-0325901 DC0HRUI MK-1775 Carcinoma (Cell Line: EFM192B) [4]
MK-1775 + PD-0325901 DCYBYGQ MK-1775 Invasive ductal carcinoma (Cell Line: T-47D) [4]
MK-2206 + PD-0325901 DCZVZ9P MK-2206 Adenocarcinoma (Cell Line: CAOV3) [3]
MK-2206 + PD-0325901 DCB22JO MK-2206 Adenocarcinoma (Cell Line: OVCAR3) [3]
MK-2206 + PD-0325901 DCWFQB4 MK-2206 Adenocarcinoma (Cell Line: A427) [3]
MK-2206 + PD-0325901 DCAKRPF MK-2206 Adenocarcinoma (Cell Line: NCIH1650) [3]
MK-2206 + PD-0325901 DCIQZ42 MK-2206 Adenocarcinoma (Cell Line: NCIH2122) [3]
MK-2206 + PD-0325901 DCYF3YD MK-2206 Adenocarcinoma (Cell Line: NCIH23) [3]
MK-2206 + PD-0325901 DC4NDC0 MK-2206 Adenocarcinoma (Cell Line: COLO320DM) [3]
MK-2206 + PD-0325901 DC4X7RY MK-2206 Adenocarcinoma (Cell Line: DLD1) [3]
MK-2206 + PD-0325901 DCPG3V8 MK-2206 Adenocarcinoma (Cell Line: HT29) [3]
MK-2206 + PD-0325901 DCYYWX6 MK-2206 Amelanotic melanoma (Cell Line: A2058) [3]
MK-2206 + PD-0325901 DCLA14V MK-2206 Germ cell tumour (Cell Line: PA1) [3]
MK-2206 + PD-0325901 DC3OCBP MK-2206 Hodgkin lymphoma (Cell Line: U-HO1) [3]
MK-2206 + PD-0325901 DC51XGW MK-2206 Large cell lung carcinoma (Cell Line: NCI-H460) [3]
MK-2206 + PD-0325901 DCPUCRG MK-2206 Malignant melanoma (Cell Line: RPMI7951) [3]
MK-2206 + PD-0325901 DCC6Q3J MK-2206 Malignant melanoma (Cell Line: UACC62) [3]
MK-2206 + PD-0325901 DCLL49C MK-2206 Non small cell carcinoma (Cell Line: SKMES1) [3]
MK-2206 + PD-0325901 DCYE2H2 MK-2206 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
MK-2206 + PD-0325901 DCKEM2B MK-2206 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
MK-2206 + PD-0325901 DCCUPDI MK-2206 Prostate carcinoma (Cell Line: LNCAP) [3]
MK-2206 + PD-0325901 DCUGL3V MK-2206 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
MK-2206 + PD-0325901 DCEUWNY MK-2206 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
MK-2206 + PD-0325901 DCBUNOQ MK-2206 Breast carcinoma (Cell Line: KPL1) [4]
MK-2206 + PD-0325901 DC0ZJLL MK-2206 Carcinoma (Cell Line: OV90) [4]
MK-2206 + PD-0325901 DCSWMN5 MK-2206 Carcinoma (Cell Line: EFM192B) [4]
MK-2206 + PD-0325901 DCLOVO9 MK-2206 Invasive ductal carcinoma (Cell Line: T-47D) [4]
MK-2206 + PD-0325901 DCGKU9V MK-2206 Rectal adenocarcinoma (Cell Line: SW837) [4]
MK-5108 + PD-0325901 DC0Q87X MK-5108 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
MK-5108 + PD-0325901 DC80NPC MK-5108 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
MK-5108 + PD-0325901 DCGXIRR MK-5108 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
MK-5108 + PD-0325901 DC7P8L1 MK-5108 Breast carcinoma (Cell Line: KPL1) [4]
MK-5108 + PD-0325901 DCME9QY MK-5108 Breast carcinoma (Cell Line: OCUBM) [4]
MK-5108 + PD-0325901 DC08PA0 MK-5108 Invasive ductal carcinoma (Cell Line: T-47D) [4]
MK-5108 + PD-0325901 DCUM7NG MK-5108 Adenocarcinoma (Cell Line: CAOV3) [2]
MK-5108 + PD-0325901 DCP5FA4 MK-5108 Adenocarcinoma (Cell Line: NCIH23) [2]
MK-5108 + PD-0325901 DCR2KEB MK-5108 Adenocarcinoma (Cell Line: DLD1) [2]
MK-5108 + PD-0325901 DCZ9FXX MK-5108 Amelanotic melanoma (Cell Line: A2058) [2]
MK-5108 + PD-0325901 DCTCC4X MK-5108 Large cell lung carcinoma (Cell Line: NCI-H460) [2]
MK-5108 + PD-0325901 DCVMAWB MK-5108 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [2]
MK-5108 + PD-0325901 DCL07DN MK-5108 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
NVP-AUY922 + PD-0325901 DC7685M NVP-AUY922 Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [3]
Panobinostat + PD-0325901 DCFA8JI Panobinostat Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [3]
PD-0325901 + Gefitinib DCCCPG1 Gefitinib Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [3]
PD-0325901 + Gefitinib DCJY4RK Gefitinib Primitive neuroectodermal tumor (Cell Line: TC-32) [3]
PD-0325901 + PD-0325901 DC49TEV PD-0325901 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
PD-0325901 + Lapatinib DCERNQ6 Lapatinib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
PD-0325901 + MK-1775 DCODYQX MK-1775 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
PD-0325901 + JQ1 DCQSVFV JQ1 Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [3]
PD-0325901 + PMID28460551-Compound-2 DC9CNJ3 PMID28460551-Compound-2 Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
PD-0325901 + Prochlorperazine DCV5PRI Prochlorperazine Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [3]
PD-0325901 + Prochlorperazine DCVPAAL Prochlorperazine Primitive neuroectodermal tumor (Cell Line: TC-32) [3]
PD-0325901 + Panobinostat DC06ALU Panobinostat Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
PD-0325901 + Panobinostat DC8IXDY Panobinostat Primitive neuroectodermal tumor (Cell Line: TC-32) [3]
PD-0325901 + RTB101 DCHG6IW RTB101 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
PD-0325901 + SCH-900776 DCTPGKQ SCH-900776 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
PD-0325901 + Alvespimycin hydrochloride DCIY37S Alvespimycin hydrochloride Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
PD-0325901 + Lenalidomide DC5C5RU Lenalidomide Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
PD-0325901 + Olaparib DCB66T4 Olaparib Ewing sarcoma (Cell Line: EW-8) [3]
PD-0325901 + LY2835219 DCW2KK0 LY2835219 Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
PD-0325901 + 10-hydroxycamptothecin DC3M3GN 10-hydroxycamptothecin Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
PD-0325901 + CUDC-101 DCO2LUW CUDC-101 Primitive neuroectodermal tumor (Cell Line: TC-32) [3]
PD-0325901 + SNX-2112 DC6KGR0 SNX-2112 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
PD-0325901 + Plinabulin DCWYGRN Plinabulin Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
PD-0325901 + THAPSIGARGIN DC4296D THAPSIGARGIN Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [3]
PD-0325901 + THAPSIGARGIN DCVZCFW THAPSIGARGIN Primitive neuroectodermal tumor (Cell Line: TC-32) [3]
PD-0325901 + Marizomib DC8E6S6 Marizomib Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
PD-0325901 + MK-5108 DCP1163 MK-5108 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
PD-0325901 + Tamoxifen DC62387 Tamoxifen Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [3]
PD-0325901 + Tamoxifen DCOQE2L Tamoxifen Primitive neuroectodermal tumor (Cell Line: TC-32) [3]
PD-0325901 + MK-4827 DC6ALAV MK-4827 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
PD-0325901 + Idarubicin DC3NU0M Idarubicin Glioblastoma? (Cell Line: T98G) [3]
PD-0325901 + Lomustine DCTIPEI Lomustine Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
PD-0325901 + Ciclopirox DCURBNN Ciclopirox Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [3]
PD-0325901 + Bortezomib DC2MZ9T Bortezomib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
PD-0325901 + BMS-754807 DC9VZXK BMS-754807 Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
PD-0325901 + Sorafenib DCS22C5 Sorafenib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
PD-0325901 + Prazosin DCKWZGL Prazosin Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [3]
PD-0325901 + PF-562271 DCFMSWD PF-562271 Diffuse large B cell lymphoma (Cell Line: TMD8) [3]
PD-0325901 + PF-562271 DCOOVFX PF-562271 Primitive neuroectodermal tumor (Cell Line: TC-32) [3]
PD-0325901 + Fludarabine DCMW9C0 Fludarabine Ewing sarcoma (Cell Line: TC-71) [3]
PD-0325901 + Auranofin DCRXA9P Auranofin Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [3]
PD-0325901 + Auranofin DCK92WD Auranofin Primitive neuroectodermal tumor (Cell Line: TC-32) [3]
PD-0325901 + Vorinostat DCLVSII Vorinostat Ewing sarcoma (Cell Line: TC-71) [3]
PD-0325901 + Vorinostat DCKKWU2 Vorinostat Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
PD-0325901 + Ibrutinib DCWFXV9 Ibrutinib Diffuse large B cell lymphoma (Cell Line: TMD8) [3]
PD-0325901 + Dasatinib DCC9DG6 Dasatinib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
PD-0325901 + PD-0325901 DCB7YDY PD-0325901 Breast carcinoma (Cell Line: OCUBM) [4]
PD-0325901 + PD-0325901 DC16S71 PD-0325901 Carcinoma (Cell Line: EFM192B) [4]
PD-0325901 + PD-0325901 DCSFR7G PD-0325901 Carcinoma (Cell Line: MDAMB436) [4]
PD-0325901 + PD-0325901 DCJSCJG PD-0325901 Colon carcinoma (Cell Line: RKO) [4]
PD-0325901 + PD-0325901 DCZT5DU PD-0325901 Invasive ductal carcinoma (Cell Line: T-47D) [4]
PD-0325901 + Lapatinib DCKKNGJ Lapatinib Breast carcinoma (Cell Line: KPL1) [4]
PD-0325901 + Lapatinib DC2J4BT Lapatinib Breast carcinoma (Cell Line: OCUBM) [4]
PD-0325901 + Lapatinib DCR6XGK Lapatinib Carcinoma (Cell Line: EFM192B) [4]
PD-0325901 + Lapatinib DC6PCU2 Lapatinib Carcinoma (Cell Line: MDAMB436) [4]
PD-0325901 + Lapatinib DCUI661 Lapatinib Colon adenocarcinoma (Cell Line: LOVO) [4]
PD-0325901 + Lapatinib DCJRTDJ Lapatinib Colon carcinoma (Cell Line: RKO) [4]
PD-0325901 + Lapatinib DCCB57U Lapatinib Invasive ductal carcinoma (Cell Line: T-47D) [4]
PD-0325901 + Lapatinib DCUY2HO Lapatinib Rectal adenocarcinoma (Cell Line: SW837) [4]
PD-0325901 + MK-1775 DC7O6JW MK-1775 Breast carcinoma (Cell Line: KPL1) [4]
PD-0325901 + MK-1775 DC7OQUQ MK-1775 Breast carcinoma (Cell Line: OCUBM) [4]
PD-0325901 + MK-1775 DCTK7SR MK-1775 Carcinoma (Cell Line: OV90) [4]
PD-0325901 + MK-1775 DCI5H81 MK-1775 Carcinoma (Cell Line: EFM192B) [4]
PD-0325901 + MK-1775 DCRYJXE MK-1775 Carcinoma (Cell Line: MDAMB436) [4]
PD-0325901 + MK-1775 DC5DWQJ MK-1775 Colon adenocarcinoma (Cell Line: LOVO) [4]
PD-0325901 + MK-1775 DCPUR97 MK-1775 Colon carcinoma (Cell Line: RKO) [4]
PD-0325901 + MK-1775 DCKVWNX MK-1775 Invasive ductal carcinoma (Cell Line: T-47D) [4]
PD-0325901 + MK-1775 DCTQ4YH MK-1775 Rectal adenocarcinoma (Cell Line: SW837) [4]
PD-0325901 + RTB101 DCTM3VE RTB101 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
PD-0325901 + RTB101 DCKZH62 RTB101 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
PD-0325901 + RTB101 DCEDYFA RTB101 Breast carcinoma (Cell Line: ZR751) [4]
PD-0325901 + RTB101 DC2ILKL RTB101 Breast carcinoma (Cell Line: KPL1) [4]
PD-0325901 + RTB101 DCPM3II RTB101 Breast carcinoma (Cell Line: OCUBM) [4]
PD-0325901 + RTB101 DCN3XQN RTB101 Carcinoma (Cell Line: OV90) [4]
PD-0325901 + RTB101 DC6WT64 RTB101 Carcinoma (Cell Line: EFM192B) [4]
PD-0325901 + RTB101 DCPUY32 RTB101 Carcinoma (Cell Line: MDAMB436) [4]
PD-0325901 + RTB101 DCN0JL8 RTB101 Colon adenocarcinoma (Cell Line: LOVO) [4]
PD-0325901 + RTB101 DCH9U1A RTB101 Colon carcinoma (Cell Line: RKO) [4]
PD-0325901 + RTB101 DCRND9F RTB101 Invasive ductal carcinoma (Cell Line: T-47D) [4]
PD-0325901 + RTB101 DC86USJ RTB101 Rectal adenocarcinoma (Cell Line: SW837) [4]
PD-0325901 + SCH-900776 DCJD918 SCH-900776 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
PD-0325901 + SCH-900776 DCDJ47S SCH-900776 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
PD-0325901 + SCH-900776 DC2KRHM SCH-900776 Breast carcinoma (Cell Line: ZR751) [4]
PD-0325901 + SCH-900776 DCIJO1L SCH-900776 Breast carcinoma (Cell Line: KPL1) [4]
PD-0325901 + SCH-900776 DCRV0EF SCH-900776 Breast carcinoma (Cell Line: OCUBM) [4]
PD-0325901 + SCH-900776 DCU8VN3 SCH-900776 Carcinoma (Cell Line: OV90) [4]
PD-0325901 + SCH-900776 DC0DYS3 SCH-900776 Carcinoma (Cell Line: EFM192B) [4]
PD-0325901 + SCH-900776 DCJBXEG SCH-900776 Carcinoma (Cell Line: MDAMB436) [4]
PD-0325901 + SCH-900776 DCKUOMF SCH-900776 Colon adenocarcinoma (Cell Line: LOVO) [4]
PD-0325901 + SCH-900776 DC8ER24 SCH-900776 Colon carcinoma (Cell Line: RKO) [4]
PD-0325901 + SCH-900776 DCCTA4P SCH-900776 Invasive ductal carcinoma (Cell Line: T-47D) [4]
PD-0325901 + SCH-900776 DCPN5FX SCH-900776 Rectal adenocarcinoma (Cell Line: SW837) [4]
PD-0325901 + 10-hydroxycamptothecin DCULI4N 10-hydroxycamptothecin Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
PD-0325901 + 10-hydroxycamptothecin DCLZJYD 10-hydroxycamptothecin Breast carcinoma (Cell Line: OCUBM) [4]
PD-0325901 + 10-hydroxycamptothecin DCCBSPR 10-hydroxycamptothecin Carcinoma (Cell Line: OV90) [4]
PD-0325901 + 10-hydroxycamptothecin DC0IGVP 10-hydroxycamptothecin Carcinoma (Cell Line: EFM192B) [4]
PD-0325901 + 10-hydroxycamptothecin DCOULPS 10-hydroxycamptothecin Carcinoma (Cell Line: MDAMB436) [4]
PD-0325901 + 10-hydroxycamptothecin DCQ6IVY 10-hydroxycamptothecin Colon adenocarcinoma (Cell Line: LOVO) [4]
PD-0325901 + 10-hydroxycamptothecin DCWP4UV 10-hydroxycamptothecin Colon carcinoma (Cell Line: RKO) [4]
PD-0325901 + 10-hydroxycamptothecin DCORORD 10-hydroxycamptothecin Rectal adenocarcinoma (Cell Line: SW837) [4]
PD-0325901 + SNX-2112 DCMYQS5 SNX-2112 Breast carcinoma (Cell Line: KPL1) [4]
PD-0325901 + SNX-2112 DC0GK1Z SNX-2112 Breast carcinoma (Cell Line: OCUBM) [4]
PD-0325901 + SNX-2112 DCNRE8I SNX-2112 Carcinoma (Cell Line: OV90) [4]
PD-0325901 + SNX-2112 DCJDKVF SNX-2112 Carcinoma (Cell Line: EFM192B) [4]
PD-0325901 + SNX-2112 DC1FG8K SNX-2112 Carcinoma (Cell Line: MDAMB436) [4]
PD-0325901 + SNX-2112 DCNG1JW SNX-2112 Colon adenocarcinoma (Cell Line: LOVO) [4]
PD-0325901 + SNX-2112 DC4Q9RT SNX-2112 Colon carcinoma (Cell Line: RKO) [4]
PD-0325901 + SNX-2112 DC31BKC SNX-2112 Invasive ductal carcinoma (Cell Line: T-47D) [4]
PD-0325901 + SNX-2112 DCWCK4J SNX-2112 Rectal adenocarcinoma (Cell Line: SW837) [4]
PD-0325901 + Erlotinib DCKR6RN Erlotinib Breast carcinoma (Cell Line: KPL1) [4]
PD-0325901 + Erlotinib DCZDWP3 Erlotinib Breast carcinoma (Cell Line: OCUBM) [4]
PD-0325901 + Erlotinib DCD2M1L Erlotinib Carcinoma (Cell Line: EFM192B) [4]
PD-0325901 + Erlotinib DC207QM Erlotinib Carcinoma (Cell Line: MDAMB436) [4]
PD-0325901 + Erlotinib DCQNU1I Erlotinib Colon carcinoma (Cell Line: RKO) [4]
PD-0325901 + Erlotinib DCLFMBZ Erlotinib Rectal adenocarcinoma (Cell Line: SW837) [4]
PD-0325901 + MK-5108 DCL0UVU MK-5108 Breast carcinoma (Cell Line: KPL1) [4]
PD-0325901 + MK-5108 DCZ63ZD MK-5108 Breast carcinoma (Cell Line: OCUBM) [4]
PD-0325901 + MK-5108 DC9H9ZR MK-5108 Carcinoma (Cell Line: EFM192B) [4]
PD-0325901 + MK-5108 DC13JAN MK-5108 Carcinoma (Cell Line: MDAMB436) [4]
PD-0325901 + MK-5108 DCPK3XK MK-5108 Invasive ductal carcinoma (Cell Line: T-47D) [4]
PD-0325901 + Ridaforolimus DC43W7M Ridaforolimus Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
PD-0325901 + Ridaforolimus DCDDROZ Ridaforolimus Breast carcinoma (Cell Line: KPL1) [4]
PD-0325901 + Ridaforolimus DC0360N Ridaforolimus Breast carcinoma (Cell Line: OCUBM) [4]
PD-0325901 + Ridaforolimus DCKRH4A Ridaforolimus Colon carcinoma (Cell Line: RKO) [4]
PD-0325901 + Ridaforolimus DCP4H5P Ridaforolimus Invasive ductal carcinoma (Cell Line: T-47D) [4]
PD-0325901 + Ridaforolimus DC7PT5Z Ridaforolimus Rectal adenocarcinoma (Cell Line: SW837) [4]
PD-0325901 + MK-4827 DC7RHBL MK-4827 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
PD-0325901 + MK-4827 DCT1DD8 MK-4827 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
PD-0325901 + MK-4827 DCHE11I MK-4827 Breast carcinoma (Cell Line: KPL1) [4]
PD-0325901 + MK-4827 DCZB8XI MK-4827 Breast carcinoma (Cell Line: OCUBM) [4]
PD-0325901 + MK-4827 DCDYPBP MK-4827 Carcinoma (Cell Line: OV90) [4]
PD-0325901 + MK-4827 DCFMCTM MK-4827 Carcinoma (Cell Line: EFM192B) [4]
PD-0325901 + MK-4827 DCSZ68H MK-4827 Carcinoma (Cell Line: MDAMB436) [4]
PD-0325901 + MK-4827 DC3BO78 MK-4827 Colon adenocarcinoma (Cell Line: LOVO) [4]
PD-0325901 + MK-4827 DCU8IG6 MK-4827 Colon carcinoma (Cell Line: RKO) [4]
PD-0325901 + MK-4827 DCHAHNU MK-4827 Invasive ductal carcinoma (Cell Line: T-47D) [4]
PD-0325901 + MK-4827 DC2IQNQ MK-4827 Rectal adenocarcinoma (Cell Line: SW837) [4]
PD-0325901 + Lomustine DCR43TM Lomustine Breast carcinoma (Cell Line: KPL1) [4]
PD-0325901 + Lomustine DCQZSFA Lomustine Breast carcinoma (Cell Line: OCUBM) [4]
PD-0325901 + Lomustine DC0WKM8 Lomustine Carcinoma (Cell Line: EFM192B) [4]
PD-0325901 + Lomustine DCBVC8K Lomustine Invasive ductal carcinoma (Cell Line: T-47D) [4]
PD-0325901 + Bortezomib DC88KZ8 Bortezomib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
PD-0325901 + Bortezomib DCUI1S7 Bortezomib Breast carcinoma (Cell Line: ZR751) [4]
PD-0325901 + Bortezomib DC5SK21 Bortezomib Breast carcinoma (Cell Line: KPL1) [4]
PD-0325901 + Bortezomib DC6J6U9 Bortezomib Carcinoma (Cell Line: EFM192B) [4]
PD-0325901 + Bortezomib DC9VRRN Bortezomib Colon adenocarcinoma (Cell Line: LOVO) [4]
PD-0325901 + Bortezomib DCUMFU0 Bortezomib Rectal adenocarcinoma (Cell Line: SW837) [4]
PD-0325901 + GSK525762 DCVYBRZ GSK525762 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
PD-0325901 + GSK525762 DC5SDMT GSK525762 Carcinoma (Cell Line: EFM192B) [4]
PD-0325901 + GSK525762 DCC82Q6 GSK525762 Invasive ductal carcinoma (Cell Line: T-47D) [4]
PD-0325901 + Sorafenib DC560M7 Sorafenib Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
PD-0325901 + Sorafenib DCTKU3C Sorafenib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
PD-0325901 + Sorafenib DC50RW8 Sorafenib Breast carcinoma (Cell Line: ZR751) [4]
PD-0325901 + Sorafenib DC76ANC Sorafenib Breast carcinoma (Cell Line: KPL1) [4]
PD-0325901 + Sorafenib DC3IV0K Sorafenib Breast carcinoma (Cell Line: OCUBM) [4]
PD-0325901 + Sorafenib DCTXBBQ Sorafenib Carcinoma (Cell Line: OV90) [4]
PD-0325901 + Sorafenib DCUD4H1 Sorafenib Carcinoma (Cell Line: EFM192B) [4]
PD-0325901 + Sorafenib DCXLCWZ Sorafenib Colon adenocarcinoma (Cell Line: LOVO) [4]
PD-0325901 + Sorafenib DCVU0DP Sorafenib Colon carcinoma (Cell Line: RKO) [4]
PD-0325901 + Sorafenib DC596MY Sorafenib Invasive ductal carcinoma (Cell Line: T-47D) [4]
PD-0325901 + Sorafenib DCQ3734 Sorafenib Rectal adenocarcinoma (Cell Line: SW837) [4]
PD-0325901 + MK-2206 DC6ED9P MK-2206 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
PD-0325901 + MK-2206 DCNQ1T8 MK-2206 Breast carcinoma (Cell Line: KPL1) [4]
PD-0325901 + MK-2206 DCGL1QF MK-2206 Breast carcinoma (Cell Line: OCUBM) [4]
PD-0325901 + MK-2206 DCPW344 MK-2206 Carcinoma (Cell Line: OV90) [4]
PD-0325901 + MK-2206 DCQROCU MK-2206 Carcinoma (Cell Line: EFM192B) [4]
PD-0325901 + MK-2206 DCYHVE4 MK-2206 Carcinoma (Cell Line: MDAMB436) [4]
PD-0325901 + MK-2206 DCIQZ0R MK-2206 Colon carcinoma (Cell Line: RKO) [4]
PD-0325901 + MK-2206 DC1LZNS MK-2206 Invasive ductal carcinoma (Cell Line: T-47D) [4]
PD-0325901 + MK-2206 DC69JPT MK-2206 Rectal adenocarcinoma (Cell Line: SW837) [4]
PD-0325901 + Vorinostat DCPR3JG Vorinostat Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
PD-0325901 + Vorinostat DCMHLSU Vorinostat Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
PD-0325901 + Vorinostat DCRGZPJ Vorinostat Breast carcinoma (Cell Line: KPL1) [4]
PD-0325901 + Vorinostat DC87UQ0 Vorinostat Breast carcinoma (Cell Line: OCUBM) [4]
PD-0325901 + Vorinostat DC128K8 Vorinostat Carcinoma (Cell Line: OV90) [4]
PD-0325901 + Vorinostat DCW66OZ Vorinostat Colon carcinoma (Cell Line: RKO) [4]
PD-0325901 + Vorinostat DC0CIZE Vorinostat Invasive ductal carcinoma (Cell Line: T-47D) [4]
PD-0325901 + Vorinostat DCSDKWT Vorinostat Rectal adenocarcinoma (Cell Line: SW837) [4]
PD-0325901 + Dasatinib DCFZMUL Dasatinib Breast carcinoma (Cell Line: KPL1) [4]
PD-0325901 + Dasatinib DCO7WUY Dasatinib Breast carcinoma (Cell Line: OCUBM) [4]
PD-0325901 + Dasatinib DCXMAB7 Dasatinib Carcinoma (Cell Line: OV90) [4]
PD-0325901 + Dasatinib DCE34VG Dasatinib Carcinoma (Cell Line: EFM192B) [4]
PD-0325901 + Dasatinib DCXLPF4 Dasatinib Carcinoma (Cell Line: MDAMB436) [4]
PD-0325901 + Dasatinib DCDCPW3 Dasatinib Colon carcinoma (Cell Line: RKO) [4]
PD-0325901 + Dasatinib DCR02ZL Dasatinib Invasive ductal carcinoma (Cell Line: T-47D) [4]
PD-0325901 + Dasatinib DC34X96 Dasatinib Rectal adenocarcinoma (Cell Line: SW837) [4]
PD-0325901 + PD-0325901 DCMJKY3 PD-0325901 Adenocarcinoma (Cell Line: CAOV3) [2]
PD-0325901 + PD-0325901 DC6EVMQ PD-0325901 Adenocarcinoma (Cell Line: OVCAR3) [2]
PD-0325901 + PD-0325901 DCU944I PD-0325901 Adenocarcinoma (Cell Line: A427) [2]
PD-0325901 + PD-0325901 DCAIWGQ PD-0325901 Adenocarcinoma (Cell Line: NCIH1650) [2]
PD-0325901 + PD-0325901 DCBXZMB PD-0325901 Adenocarcinoma (Cell Line: NCIH2122) [2]
PD-0325901 + PD-0325901 DC8FWEY PD-0325901 Adenocarcinoma (Cell Line: NCIH23) [2]
PD-0325901 + PD-0325901 DC620KT PD-0325901 Adenocarcinoma (Cell Line: COLO320DM) [2]
PD-0325901 + PD-0325901 DC21YHR PD-0325901 Adenocarcinoma (Cell Line: DLD1) [2]
PD-0325901 + PD-0325901 DCLGE25 PD-0325901 Adenocarcinoma (Cell Line: HCT116) [2]
PD-0325901 + PD-0325901 DCP9VR7 PD-0325901 Adenocarcinoma (Cell Line: HT29) [2]
PD-0325901 + PD-0325901 DC3CEY8 PD-0325901 Amelanotic melanoma (Cell Line: A2058) [2]
PD-0325901 + PD-0325901 DC3KHJ2 PD-0325901 Germ cell tumour (Cell Line: PA1) [2]
PD-0325901 + PD-0325901 DCFXDKP PD-0325901 Large cell lung carcinoma (Cell Line: NCI-H460) [2]
PD-0325901 + PD-0325901 DC70KM1 PD-0325901 Malignant melanoma (Cell Line: A375) [2]
PD-0325901 + PD-0325901 DCU2KP6 PD-0325901 Malignant melanoma (Cell Line: HT144) [2]
PD-0325901 + PD-0325901 DC4H8TI PD-0325901 Malignant melanoma (Cell Line: RPMI7951) [2]
PD-0325901 + PD-0325901 DC1O11K PD-0325901 Malignant melanoma (Cell Line: SKMEL30) [2]
PD-0325901 + PD-0325901 DCV9YR2 PD-0325901 Mesothelioma (Cell Line: MSTO) [2]
PD-0325901 + PD-0325901 DC90I1V PD-0325901 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [2]
PD-0325901 + PD-0325901 DCHRTPQ PD-0325901 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
PD-0325901 + PD-0325901 DCBBCL0 PD-0325901 Prostate carcinoma (Cell Line: VCAP) [2]
PD-0325901 + Lapatinib DCXSDN6 Lapatinib Adenocarcinoma (Cell Line: CAOV3) [2]
PD-0325901 + Lapatinib DCXJO0W Lapatinib Adenocarcinoma (Cell Line: A427) [2]
PD-0325901 + Lapatinib DCR78NF Lapatinib Adenocarcinoma (Cell Line: NCIH1650) [2]
PD-0325901 + Lapatinib DCVT3VI Lapatinib Adenocarcinoma (Cell Line: NCIH2122) [2]
PD-0325901 + Lapatinib DCOJZFW Lapatinib Adenocarcinoma (Cell Line: NCIH23) [2]
PD-0325901 + Lapatinib DC0HN10 Lapatinib Adenocarcinoma (Cell Line: NCIH520) [2]
PD-0325901 + Lapatinib DC94F7Y Lapatinib Adenocarcinoma (Cell Line: COLO320DM) [2]
PD-0325901 + Lapatinib DCQQMQK Lapatinib Adenocarcinoma (Cell Line: DLD1) [2]
PD-0325901 + Lapatinib DCLP8DL Lapatinib Amelanotic melanoma (Cell Line: A2058) [2]
PD-0325901 + Lapatinib DCMASXK Lapatinib Germ cell tumour (Cell Line: PA1) [2]
PD-0325901 + Lapatinib DCXY24W Lapatinib Malignant melanoma (Cell Line: HT144) [2]
PD-0325901 + Lapatinib DCQH2CL Lapatinib Malignant melanoma (Cell Line: RPMI7951) [2]
PD-0325901 + Lapatinib DC6XLIR Lapatinib Malignant melanoma (Cell Line: SKMEL30) [2]
PD-0325901 + Lapatinib DCHTPI1 Lapatinib Malignant melanoma (Cell Line: UACC62) [2]
PD-0325901 + Lapatinib DCN7XNQ Lapatinib Mesothelioma (Cell Line: MSTO) [2]
PD-0325901 + Lapatinib DC7BUTH Lapatinib Non small cell carcinoma (Cell Line: SKMES1) [2]
PD-0325901 + Lapatinib DCEJZX3 Lapatinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [2]
PD-0325901 + Lapatinib DC1XLUB Lapatinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
PD-0325901 + Lapatinib DC51RDB Lapatinib Prostate carcinoma (Cell Line: VCAP) [2]
PD-0325901 + MK-1775 DC52AAC MK-1775 Adenocarcinoma (Cell Line: CAOV3) [2]
PD-0325901 + MK-1775 DCBKUKX MK-1775 Adenocarcinoma (Cell Line: A427) [2]
PD-0325901 + MK-1775 DC28KYC MK-1775 Adenocarcinoma (Cell Line: NCIH2122) [2]
PD-0325901 + MK-1775 DCO2K32 MK-1775 Adenocarcinoma (Cell Line: NCIH23) [2]
PD-0325901 + MK-1775 DCT7X54 MK-1775 Adenocarcinoma (Cell Line: NCIH520) [2]
PD-0325901 + MK-1775 DCWY96T MK-1775 Adenocarcinoma (Cell Line: COLO320DM) [2]
PD-0325901 + MK-1775 DCDCKX0 MK-1775 Adenocarcinoma (Cell Line: HCT116) [2]
PD-0325901 + MK-1775 DC7WLDW MK-1775 Adenocarcinoma (Cell Line: HT29) [2]
PD-0325901 + MK-1775 DCL4ZJK MK-1775 Adenocarcinoma (Cell Line: SW-620) [2]
PD-0325901 + MK-1775 DCETMOX MK-1775 Amelanotic melanoma (Cell Line: A2058) [2]
PD-0325901 + MK-1775 DCYA9O9 MK-1775 Embryonal rhabdomyosarcoma (Cell Line: Rh36) [2]
PD-0325901 + MK-1775 DCVBZ23 MK-1775 Germ cell tumour (Cell Line: PA1) [2]
PD-0325901 + MK-1775 DCS9I1Z MK-1775 Hodgkin lymphoma (Cell Line: U-HO1) [2]
PD-0325901 + MK-1775 DC65KUW MK-1775 Large cell lung carcinoma (Cell Line: NCI-H460) [2]
PD-0325901 + MK-1775 DCJJM4H MK-1775 Malignant melanoma (Cell Line: A375) [2]
PD-0325901 + MK-1775 DCRE1RK MK-1775 Malignant melanoma (Cell Line: HT144) [2]
PD-0325901 + MK-1775 DCFHXFG MK-1775 Malignant melanoma (Cell Line: RPMI7951) [2]
PD-0325901 + MK-1775 DC7Z7WH MK-1775 Malignant melanoma (Cell Line: SKMEL30) [2]
PD-0325901 + MK-1775 DC17Y5D MK-1775 Malignant melanoma (Cell Line: UACC62) [2]
PD-0325901 + MK-1775 DCHZLFO MK-1775 Non small cell carcinoma (Cell Line: SKMES1) [2]
PD-0325901 + MK-1775 DCNY7EA MK-1775 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [2]
PD-0325901 + MK-1775 DC9PZHI MK-1775 Prostate carcinoma (Cell Line: LNCAP) [2]
PD-0325901 + MK-1775 DCXVYDI MK-1775 Prostate carcinoma (Cell Line: VCAP) [2]
PD-0325901 + RTB101 DCFB7O3 RTB101 Adenocarcinoma (Cell Line: CAOV3) [2]
PD-0325901 + RTB101 DC5NU0B RTB101 Adenocarcinoma (Cell Line: OVCAR3) [2]
PD-0325901 + RTB101 DCHYLB2 RTB101 Adenocarcinoma (Cell Line: A427) [2]
PD-0325901 + RTB101 DCY3E9X RTB101 Adenocarcinoma (Cell Line: NCIH1650) [2]
PD-0325901 + RTB101 DCHX48N RTB101 Adenocarcinoma (Cell Line: NCIH2122) [2]
PD-0325901 + RTB101 DCZSQAH RTB101 Adenocarcinoma (Cell Line: NCIH23) [2]
PD-0325901 + RTB101 DC7NVA4 RTB101 Adenocarcinoma (Cell Line: NCIH520) [2]
PD-0325901 + RTB101 DCLN7SX RTB101 Adenocarcinoma (Cell Line: COLO320DM) [2]
PD-0325901 + RTB101 DCN3FID RTB101 Adenocarcinoma (Cell Line: DLD1) [2]
PD-0325901 + RTB101 DCW0LPT RTB101 Adenocarcinoma (Cell Line: HCT116) [2]
PD-0325901 + RTB101 DCIUYQX RTB101 Adenocarcinoma (Cell Line: HT29) [2]
PD-0325901 + RTB101 DCFV71Z RTB101 Adenocarcinoma (Cell Line: SW-620) [2]
PD-0325901 + RTB101 DCBI61E RTB101 Amelanotic melanoma (Cell Line: A2058) [2]
PD-0325901 + RTB101 DCZZBRM RTB101 Germ cell tumour (Cell Line: PA1) [2]
PD-0325901 + RTB101 DCEPD3N RTB101 Large cell lung carcinoma (Cell Line: NCI-H460) [2]
PD-0325901 + RTB101 DC7FWAR RTB101 Malignant melanoma (Cell Line: A375) [2]
PD-0325901 + RTB101 DC9WGZO RTB101 Malignant melanoma (Cell Line: HT144) [2]
PD-0325901 + RTB101 DC3VYTE RTB101 Malignant melanoma (Cell Line: RPMI7951) [2]
PD-0325901 + RTB101 DCUX0F4 RTB101 Malignant melanoma (Cell Line: SKMEL30) [2]
PD-0325901 + RTB101 DCGAX8R RTB101 Malignant melanoma (Cell Line: UACC62) [2]
PD-0325901 + RTB101 DC6R2WZ RTB101 Mesothelioma (Cell Line: MSTO) [2]
PD-0325901 + RTB101 DC9WT2Z RTB101 Non small cell carcinoma (Cell Line: SKMES1) [2]
PD-0325901 + RTB101 DCE7LLI RTB101 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [2]
PD-0325901 + RTB101 DCPRLUJ RTB101 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
PD-0325901 + RTB101 DCD8UNT RTB101 Prostate carcinoma (Cell Line: LNCAP) [2]
PD-0325901 + RTB101 DC4ZVBR RTB101 Prostate carcinoma (Cell Line: VCAP) [2]
PD-0325901 + SCH-900776 DCYANX5 SCH-900776 Adenocarcinoma (Cell Line: CAOV3) [2]
PD-0325901 + SCH-900776 DC5ESLA SCH-900776 Adenocarcinoma (Cell Line: OVCAR3) [2]
PD-0325901 + SCH-900776 DCJBZHM SCH-900776 Adenocarcinoma (Cell Line: A427) [2]
PD-0325901 + SCH-900776 DCTJ42V SCH-900776 Adenocarcinoma (Cell Line: NCIH1650) [2]
PD-0325901 + SCH-900776 DCLTK66 SCH-900776 Adenocarcinoma (Cell Line: NCIH2122) [2]
PD-0325901 + SCH-900776 DCY6D4G SCH-900776 Adenocarcinoma (Cell Line: NCIH520) [2]
PD-0325901 + SCH-900776 DCYS15M SCH-900776 Adenocarcinoma (Cell Line: NCIH23) [2]
PD-0325901 + SCH-900776 DCZX04W SCH-900776 Adenocarcinoma (Cell Line: COLO320DM) [2]
PD-0325901 + SCH-900776 DCT9MXN SCH-900776 Adenocarcinoma (Cell Line: DLD1) [2]
PD-0325901 + SCH-900776 DCDUUL8 SCH-900776 Adenocarcinoma (Cell Line: HCT116) [2]
PD-0325901 + SCH-900776 DC7HB22 SCH-900776 Adenocarcinoma (Cell Line: HT29) [2]
PD-0325901 + SCH-900776 DC22HS5 SCH-900776 Amelanotic melanoma (Cell Line: A2058) [2]
PD-0325901 + SCH-900776 DCGR703 SCH-900776 Germ cell tumour (Cell Line: PA1) [2]
PD-0325901 + SCH-900776 DCRM7NJ SCH-900776 Large cell lung carcinoma (Cell Line: NCI-H460) [2]
PD-0325901 + SCH-900776 DCUA35G SCH-900776 Malignant melanoma (Cell Line: A375) [2]
PD-0325901 + SCH-900776 DCUO06E SCH-900776 Malignant melanoma (Cell Line: HT144) [2]
PD-0325901 + SCH-900776 DCGU16B SCH-900776 Malignant melanoma (Cell Line: RPMI7951) [2]
PD-0325901 + SCH-900776 DCYXXVZ SCH-900776 Malignant melanoma (Cell Line: SKMEL30) [2]
PD-0325901 + SCH-900776 DCCQ6JF SCH-900776 Malignant melanoma (Cell Line: UACC62) [2]
PD-0325901 + SCH-900776 DC2S567 SCH-900776 Mesothelioma (Cell Line: MSTO) [2]
PD-0325901 + SCH-900776 DCRVE4Y SCH-900776 Non small cell carcinoma (Cell Line: SKMES1) [2]
PD-0325901 + SCH-900776 DC9BXKS SCH-900776 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [2]
PD-0325901 + SCH-900776 DCYRM3Z SCH-900776 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
PD-0325901 + SCH-900776 DCGPVZF SCH-900776 Prostate carcinoma (Cell Line: VCAP) [2]
PD-0325901 + SCH-900776 DC86OK9 SCH-900776 Prostate carcinoma (Cell Line: LNCAP) [2]
PD-0325901 + Fomepizole DC3CAQ5 Fomepizole Hodgkin lymphoma (Cell Line: U-HO1) [2]
PD-0325901 + Formononetin DCJ4X5T Formononetin Hodgkin lymphoma (Cell Line: U-HO1) [2]
PD-0325901 + Olaparib DCJLT0K Olaparib Embryonal rhabdomyosarcoma (Cell Line: Rh36) [2]
PD-0325901 + Olaparib DCAL6KB Olaparib Hodgkin lymphoma (Cell Line: U-HO1) [2]
PD-0325901 + 10-hydroxycamptothecin DCSW617 10-hydroxycamptothecin Adenocarcinoma (Cell Line: CAOV3) [2]
PD-0325901 + 10-hydroxycamptothecin DCGQGLV 10-hydroxycamptothecin Adenocarcinoma (Cell Line: OVCAR3) [2]
PD-0325901 + 10-hydroxycamptothecin DC512IH 10-hydroxycamptothecin Adenocarcinoma (Cell Line: A427) [2]
PD-0325901 + 10-hydroxycamptothecin DCRQTO0 10-hydroxycamptothecin Adenocarcinoma (Cell Line: NCIH1650) [2]
PD-0325901 + 10-hydroxycamptothecin DC1Z2PU 10-hydroxycamptothecin Adenocarcinoma (Cell Line: NCIH2122) [2]
PD-0325901 + 10-hydroxycamptothecin DCRC4QZ 10-hydroxycamptothecin Adenocarcinoma (Cell Line: NCIH520) [2]
PD-0325901 + 10-hydroxycamptothecin DC0JW1U 10-hydroxycamptothecin Adenocarcinoma (Cell Line: COLO320DM) [2]
PD-0325901 + 10-hydroxycamptothecin DC3NEQQ 10-hydroxycamptothecin Adenocarcinoma (Cell Line: DLD1) [2]
PD-0325901 + 10-hydroxycamptothecin DCUY83H 10-hydroxycamptothecin Adenocarcinoma (Cell Line: HT29) [2]
PD-0325901 + 10-hydroxycamptothecin DCW661X 10-hydroxycamptothecin Adenocarcinoma (Cell Line: SW-620) [2]
PD-0325901 + 10-hydroxycamptothecin DCWYFIN 10-hydroxycamptothecin Amelanotic melanoma (Cell Line: A2058) [2]
PD-0325901 + 10-hydroxycamptothecin DCMQVWX 10-hydroxycamptothecin Germ cell tumour (Cell Line: PA1) [2]
PD-0325901 + 10-hydroxycamptothecin DCPE1GD 10-hydroxycamptothecin Large cell lung carcinoma (Cell Line: NCI-H460) [2]
PD-0325901 + 10-hydroxycamptothecin DCJUER8 10-hydroxycamptothecin Malignant melanoma (Cell Line: A375) [2]
PD-0325901 + 10-hydroxycamptothecin DCBCZNG 10-hydroxycamptothecin Malignant melanoma (Cell Line: HT144) [2]
PD-0325901 + 10-hydroxycamptothecin DCC3175 10-hydroxycamptothecin Malignant melanoma (Cell Line: RPMI7951) [2]
PD-0325901 + 10-hydroxycamptothecin DC11Z6W 10-hydroxycamptothecin Malignant melanoma (Cell Line: SKMEL30) [2]
PD-0325901 + 10-hydroxycamptothecin DCVARCZ 10-hydroxycamptothecin Malignant melanoma (Cell Line: UACC62) [2]
PD-0325901 + 10-hydroxycamptothecin DCUW7E7 10-hydroxycamptothecin Mesothelioma (Cell Line: MSTO) [2]
PD-0325901 + 10-hydroxycamptothecin DCFKJTR 10-hydroxycamptothecin Non small cell carcinoma (Cell Line: SKMES1) [2]
PD-0325901 + 10-hydroxycamptothecin DCSJ851 10-hydroxycamptothecin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [2]
PD-0325901 + 10-hydroxycamptothecin DCIS3V1 10-hydroxycamptothecin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
PD-0325901 + 10-hydroxycamptothecin DCQAGLU 10-hydroxycamptothecin Prostate carcinoma (Cell Line: VCAP) [2]
PD-0325901 + Pralatrexate DCU94VI Pralatrexate Hodgkin lymphoma (Cell Line: U-HO1) [2]
PD-0325901 + SNX-2112 DCSNDDE SNX-2112 Adenocarcinoma (Cell Line: CAOV3) [2]
PD-0325901 + SNX-2112 DCHKH6K SNX-2112 Adenocarcinoma (Cell Line: OVCAR3) [2]
PD-0325901 + SNX-2112 DCNG18D SNX-2112 Adenocarcinoma (Cell Line: A427) [2]
PD-0325901 + SNX-2112 DCHEDLT SNX-2112 Adenocarcinoma (Cell Line: NCIH1650) [2]
PD-0325901 + SNX-2112 DCZSRN6 SNX-2112 Adenocarcinoma (Cell Line: NCIH2122) [2]
PD-0325901 + SNX-2112 DCTARXD SNX-2112 Adenocarcinoma (Cell Line: NCIH23) [2]
PD-0325901 + SNX-2112 DC0DDO9 SNX-2112 Adenocarcinoma (Cell Line: COLO320DM) [2]
PD-0325901 + SNX-2112 DC18WEJ SNX-2112 Adenocarcinoma (Cell Line: DLD1) [2]
PD-0325901 + SNX-2112 DCUCKY0 SNX-2112 Adenocarcinoma (Cell Line: HCT116) [2]
PD-0325901 + SNX-2112 DC8UMZO SNX-2112 Adenocarcinoma (Cell Line: SW-620) [2]
PD-0325901 + SNX-2112 DCHG904 SNX-2112 Amelanotic melanoma (Cell Line: A2058) [2]
PD-0325901 + SNX-2112 DCIGNFI SNX-2112 Germ cell tumour (Cell Line: PA1) [2]
PD-0325901 + SNX-2112 DC1JPAP SNX-2112 Large cell lung carcinoma (Cell Line: NCI-H460) [2]
PD-0325901 + SNX-2112 DCND25H SNX-2112 Malignant melanoma (Cell Line: A375) [2]
PD-0325901 + SNX-2112 DC8QBIQ SNX-2112 Malignant melanoma (Cell Line: HT144) [2]
PD-0325901 + SNX-2112 DCE9H80 SNX-2112 Malignant melanoma (Cell Line: SKMEL30) [2]
PD-0325901 + SNX-2112 DC4V47F SNX-2112 Malignant melanoma (Cell Line: UACC62) [2]
PD-0325901 + SNX-2112 DCHHMER SNX-2112 Mesothelioma (Cell Line: MSTO) [2]
PD-0325901 + SNX-2112 DC3SVN9 SNX-2112 Non small cell carcinoma (Cell Line: SKMES1) [2]
PD-0325901 + SNX-2112 DCWXOYW SNX-2112 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [2]
PD-0325901 + SNX-2112 DCNFV5E SNX-2112 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
PD-0325901 + SNX-2112 DCY12SD SNX-2112 Prostate carcinoma (Cell Line: LNCAP) [2]
PD-0325901 + SNX-2112 DCZQBMQ SNX-2112 Prostate carcinoma (Cell Line: VCAP) [2]
PD-0325901 + Erlotinib DCS1OFB Erlotinib Adenocarcinoma (Cell Line: CAOV3) [2]
PD-0325901 + Erlotinib DC4EQK5 Erlotinib Adenocarcinoma (Cell Line: OVCAR3) [2]
PD-0325901 + Erlotinib DCNSLLU Erlotinib Adenocarcinoma (Cell Line: A427) [2]
PD-0325901 + Erlotinib DCG03OG Erlotinib Adenocarcinoma (Cell Line: NCIH2122) [2]
PD-0325901 + Erlotinib DCL58UE Erlotinib Adenocarcinoma (Cell Line: NCIH23) [2]
PD-0325901 + Erlotinib DCD9KRE Erlotinib Adenocarcinoma (Cell Line: NCIH520) [2]
PD-0325901 + Erlotinib DC64NG3 Erlotinib Adenocarcinoma (Cell Line: COLO320DM) [2]
PD-0325901 + Erlotinib DCH3APZ Erlotinib Adenocarcinoma (Cell Line: DLD1) [2]
PD-0325901 + Erlotinib DCAYCOB Erlotinib Adenocarcinoma (Cell Line: HT29) [2]
PD-0325901 + Erlotinib DCI9DLZ Erlotinib Adenocarcinoma (Cell Line: SW-620) [2]
PD-0325901 + Erlotinib DCZUCBM Erlotinib Amelanotic melanoma (Cell Line: A2058) [2]
PD-0325901 + Erlotinib DCCE7WG Erlotinib Germ cell tumour (Cell Line: PA1) [2]
PD-0325901 + Erlotinib DCR88YR Erlotinib Malignant melanoma (Cell Line: A375) [2]
PD-0325901 + Erlotinib DCSDME4 Erlotinib Malignant melanoma (Cell Line: HT144) [2]
PD-0325901 + Erlotinib DCM59RN Erlotinib Malignant melanoma (Cell Line: RPMI7951) [2]
PD-0325901 + Erlotinib DC4WV0I Erlotinib Malignant melanoma (Cell Line: SKMEL30) [2]
PD-0325901 + Erlotinib DC6YBKD Erlotinib Malignant melanoma (Cell Line: UACC62) [2]
PD-0325901 + Erlotinib DCYOI3N Erlotinib Mesothelioma (Cell Line: MSTO) [2]
PD-0325901 + Erlotinib DCW9C55 Erlotinib Non small cell carcinoma (Cell Line: SKMES1) [2]
PD-0325901 + Erlotinib DCU8U0N Erlotinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [2]
PD-0325901 + Erlotinib DCMCTUX Erlotinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
PD-0325901 + Erlotinib DCXKENI Erlotinib Prostate carcinoma (Cell Line: VCAP) [2]
PD-0325901 + THAPSIGARGIN DCIAW22 THAPSIGARGIN Hodgkin lymphoma (Cell Line: U-HO1) [2]
PD-0325901 + Etoposide DC9AOIQ Etoposide Hodgkin lymphoma (Cell Line: U-HO1) [2]
PD-0325901 + MK-5108 DC4VG20 MK-5108 Adenocarcinoma (Cell Line: CAOV3) [2]
PD-0325901 + MK-5108 DCLIQTL MK-5108 Adenocarcinoma (Cell Line: A427) [2]
PD-0325901 + MK-5108 DC2BD8G MK-5108 Adenocarcinoma (Cell Line: NCIH520) [2]
PD-0325901 + MK-5108 DC6X43X MK-5108 Adenocarcinoma (Cell Line: COLO320DM) [2]
PD-0325901 + MK-5108 DCLPDB2 MK-5108 Adenocarcinoma (Cell Line: DLD1) [2]
PD-0325901 + MK-5108 DCX21OX MK-5108 Germ cell tumour (Cell Line: PA1) [2]
PD-0325901 + MK-5108 DCRABSY MK-5108 Malignant melanoma (Cell Line: HT144) [2]
PD-0325901 + MK-5108 DCMELQV MK-5108 Malignant melanoma (Cell Line: RPMI7951) [2]
PD-0325901 + MK-5108 DC6KJQX MK-5108 Malignant melanoma (Cell Line: UACC62) [2]
PD-0325901 + MK-5108 DCQ8YCC MK-5108 Mesothelioma (Cell Line: MSTO) [2]
PD-0325901 + MK-5108 DCHTKG1 MK-5108 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [2]
PD-0325901 + MK-5108 DCE0KO9 MK-5108 Prostate carcinoma (Cell Line: LNCAP) [2]
PD-0325901 + Cycloheximide DC9KS55 Cycloheximide Hodgkin lymphoma (Cell Line: U-HO1) [2]
PD-0325901 + Mitomycin DCX0M44 Mitomycin Hodgkin lymphoma (Cell Line: U-HO1) [2]
PD-0325901 + Ridaforolimus DCEVYM5 Ridaforolimus Adenocarcinoma (Cell Line: CAOV3) [2]
PD-0325901 + Ridaforolimus DC8N5SP Ridaforolimus Adenocarcinoma (Cell Line: NCIH2122) [2]
PD-0325901 + Ridaforolimus DC3PBHC Ridaforolimus Adenocarcinoma (Cell Line: NCIH23) [2]
PD-0325901 + Ridaforolimus DCHZ8B1 Ridaforolimus Adenocarcinoma (Cell Line: COLO320DM) [2]
PD-0325901 + Ridaforolimus DCM046F Ridaforolimus Adenocarcinoma (Cell Line: DLD1) [2]
PD-0325901 + Ridaforolimus DC68T45 Ridaforolimus Adenocarcinoma (Cell Line: HT29) [2]
PD-0325901 + Ridaforolimus DC7DLDF Ridaforolimus Amelanotic melanoma (Cell Line: A2058) [2]
PD-0325901 + Ridaforolimus DC1OJAA Ridaforolimus Germ cell tumour (Cell Line: PA1) [2]
PD-0325901 + Ridaforolimus DC3PYGS Ridaforolimus Malignant melanoma (Cell Line: A375) [2]
PD-0325901 + Ridaforolimus DCOKIS0 Ridaforolimus Malignant melanoma (Cell Line: HT144) [2]
PD-0325901 + Ridaforolimus DC8HXZC Ridaforolimus Mesothelioma (Cell Line: MSTO) [2]
PD-0325901 + Ridaforolimus DCKYXD2 Ridaforolimus Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [2]
PD-0325901 + Ridaforolimus DCXDY12 Ridaforolimus Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
PD-0325901 + Ridaforolimus DC4AWUB Ridaforolimus Prostate carcinoma (Cell Line: LNCAP) [2]
PD-0325901 + MK-4827 DCBMWSA MK-4827 Adenocarcinoma (Cell Line: CAOV3) [2]
PD-0325901 + MK-4827 DCUN9PE MK-4827 Adenocarcinoma (Cell Line: OVCAR3) [2]
PD-0325901 + MK-4827 DCKQZEF MK-4827 Adenocarcinoma (Cell Line: A427) [2]
PD-0325901 + MK-4827 DCNS8GB MK-4827 Adenocarcinoma (Cell Line: NCIH1650) [2]
PD-0325901 + MK-4827 DC9XLJI MK-4827 Adenocarcinoma (Cell Line: NCIH2122) [2]
PD-0325901 + MK-4827 DCSQA1C MK-4827 Adenocarcinoma (Cell Line: NCIH23) [2]
PD-0325901 + MK-4827 DCIVPT4 MK-4827 Adenocarcinoma (Cell Line: NCIH520) [2]
PD-0325901 + MK-4827 DC533HJ MK-4827 Adenocarcinoma (Cell Line: COLO320DM) [2]
PD-0325901 + MK-4827 DC1GC43 MK-4827 Adenocarcinoma (Cell Line: DLD1) [2]
PD-0325901 + MK-4827 DC3TPSP MK-4827 Adenocarcinoma (Cell Line: HCT116) [2]
PD-0325901 + MK-4827 DCUQR5Y MK-4827 Adenocarcinoma (Cell Line: HT29) [2]
PD-0325901 + MK-4827 DCULF2N MK-4827 Adenocarcinoma (Cell Line: SW-620) [2]
PD-0325901 + MK-4827 DC3JIBR MK-4827 Amelanotic melanoma (Cell Line: A2058) [2]
PD-0325901 + MK-4827 DCF42NZ MK-4827 Germ cell tumour (Cell Line: PA1) [2]
PD-0325901 + MK-4827 DCYS8IE MK-4827 Large cell lung carcinoma (Cell Line: NCI-H460) [2]
PD-0325901 + MK-4827 DC8D6F1 MK-4827 Malignant melanoma (Cell Line: A375) [2]
PD-0325901 + MK-4827 DC2QPO9 MK-4827 Malignant melanoma (Cell Line: HT144) [2]
PD-0325901 + MK-4827 DCFV4A7 MK-4827 Malignant melanoma (Cell Line: RPMI7951) [2]
PD-0325901 + MK-4827 DCHIK8R MK-4827 Malignant melanoma (Cell Line: SKMEL30) [2]
PD-0325901 + MK-4827 DCIVDQA MK-4827 Malignant melanoma (Cell Line: UACC62) [2]
PD-0325901 + MK-4827 DCC1OLM MK-4827 Mesothelioma (Cell Line: MSTO) [2]
PD-0325901 + MK-4827 DCH1X7C MK-4827 Non small cell carcinoma (Cell Line: SKMES1) [2]
PD-0325901 + MK-4827 DCLYF7K MK-4827 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [2]
PD-0325901 + MK-4827 DCBM9WB MK-4827 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
PD-0325901 + MK-4827 DC2354G MK-4827 Prostate carcinoma (Cell Line: VCAP) [2]
PD-0325901 + MK-4827 DC6COC0 MK-4827 Prostate carcinoma (Cell Line: LNCAP) [2]
PD-0325901 + Lomustine DCZLEPN Lomustine Adenocarcinoma (Cell Line: CAOV3) [2]
PD-0325901 + Lomustine DCONEFB Lomustine Adenocarcinoma (Cell Line: NCIH2122) [2]
PD-0325901 + Lomustine DCCWQLL Lomustine Adenocarcinoma (Cell Line: DLD1) [2]
PD-0325901 + Lomustine DCV0LO7 Lomustine Adenocarcinoma (Cell Line: HCT116) [2]
PD-0325901 + Lomustine DCEB44G Lomustine Amelanotic melanoma (Cell Line: A2058) [2]
PD-0325901 + Lomustine DCSXML4 Lomustine Germ cell tumour (Cell Line: PA1) [2]
PD-0325901 + Lomustine DCA7M07 Lomustine Malignant melanoma (Cell Line: HT144) [2]
PD-0325901 + Lomustine DCXJ05J Lomustine Malignant melanoma (Cell Line: RPMI7951) [2]
PD-0325901 + Lomustine DCOYUMY Lomustine Mesothelioma (Cell Line: MSTO) [2]
PD-0325901 + Lomustine DC5S7V4 Lomustine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [2]
PD-0325901 + Lomustine DCKC0C4 Lomustine Prostate carcinoma (Cell Line: LNCAP) [2]
PD-0325901 + Bortezomib DCNWPVH Bortezomib Adenocarcinoma (Cell Line: CAOV3) [2]
PD-0325901 + Bortezomib DCDZBJU Bortezomib Adenocarcinoma (Cell Line: NCIH2122) [2]
PD-0325901 + Bortezomib DCD6TDK Bortezomib Adenocarcinoma (Cell Line: COLO320DM) [2]
PD-0325901 + Bortezomib DCX8LC8 Bortezomib Large cell lung carcinoma (Cell Line: NCI-H460) [2]
PD-0325901 + Bortezomib DCGK8LO Bortezomib Malignant melanoma (Cell Line: A375) [2]
PD-0325901 + Bortezomib DCGJTQ8 Bortezomib Malignant melanoma (Cell Line: RPMI7951) [2]
PD-0325901 + Bortezomib DCRAF8G Bortezomib Mesothelioma (Cell Line: MSTO) [2]
PD-0325901 + Bortezomib DCXPSJ8 Bortezomib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [2]
PD-0325901 + Bortezomib DCB7QI1 Bortezomib Prostate carcinoma (Cell Line: LNCAP) [2]
PD-0325901 + GSK525762 DCT6FEF GSK525762 Adenocarcinoma (Cell Line: NCIH520) [2]
PD-0325901 + GSK525762 DCRH5UX GSK525762 Mesothelioma (Cell Line: MSTO) [2]
PD-0325901 + GSK525762 DCVYA37 GSK525762 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [2]
PD-0325901 + GSK525762 DCGB5B1 GSK525762 Prostate carcinoma (Cell Line: VCAP) [2]
PD-0325901 + Tetrahydrouridine DCFAJ09 Tetrahydrouridine Hodgkin lymphoma (Cell Line: U-HO1) [2]
PD-0325901 + Sorafenib DCZYYO1 Sorafenib Adenocarcinoma (Cell Line: CAOV3) [2]
PD-0325901 + Sorafenib DCVUZ8I Sorafenib Adenocarcinoma (Cell Line: OVCAR3) [2]
PD-0325901 + Sorafenib DCKZPM3 Sorafenib Adenocarcinoma (Cell Line: A427) [2]
PD-0325901 + Sorafenib DCGRZ01 Sorafenib Adenocarcinoma (Cell Line: NCIH1650) [2]
PD-0325901 + Sorafenib DC0EYTD Sorafenib Adenocarcinoma (Cell Line: NCIH2122) [2]
PD-0325901 + Sorafenib DCL93IW Sorafenib Adenocarcinoma (Cell Line: NCIH23) [2]
PD-0325901 + Sorafenib DCVZZHJ Sorafenib Adenocarcinoma (Cell Line: NCIH520) [2]
PD-0325901 + Sorafenib DCVME96 Sorafenib Adenocarcinoma (Cell Line: COLO320DM) [2]
PD-0325901 + Sorafenib DCXVS28 Sorafenib Adenocarcinoma (Cell Line: DLD1) [2]
PD-0325901 + Sorafenib DC982VC Sorafenib Adenocarcinoma (Cell Line: HCT116) [2]
PD-0325901 + Sorafenib DCN9C8O Sorafenib Adenocarcinoma (Cell Line: HT29) [2]
PD-0325901 + Sorafenib DCD500B Sorafenib Adenocarcinoma (Cell Line: SW-620) [2]
PD-0325901 + Sorafenib DCFOM1J Sorafenib Amelanotic melanoma (Cell Line: A2058) [2]
PD-0325901 + Sorafenib DCSS6RF Sorafenib Germ cell tumour (Cell Line: PA1) [2]
PD-0325901 + Sorafenib DCM1QFD Sorafenib Large cell lung carcinoma (Cell Line: NCI-H460) [2]
PD-0325901 + Sorafenib DCQ81MS Sorafenib Malignant melanoma (Cell Line: A375) [2]
PD-0325901 + Sorafenib DCKN209 Sorafenib Malignant melanoma (Cell Line: HT144) [2]
PD-0325901 + Sorafenib DC6PXVD Sorafenib Malignant melanoma (Cell Line: RPMI7951) [2]
PD-0325901 + Sorafenib DCIPK9X Sorafenib Malignant melanoma (Cell Line: SKMEL30) [2]
PD-0325901 + Sorafenib DC23UHK Sorafenib Malignant melanoma (Cell Line: UACC62) [2]
PD-0325901 + Sorafenib DC3Q403 Sorafenib Mesothelioma (Cell Line: MSTO) [2]
PD-0325901 + Sorafenib DC1T7WR Sorafenib Non small cell carcinoma (Cell Line: SKMES1) [2]
PD-0325901 + Sorafenib DCGV0DO Sorafenib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [2]
PD-0325901 + Sorafenib DCSZVM9 Sorafenib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
PD-0325901 + Sorafenib DC1FZ7N Sorafenib Prostate carcinoma (Cell Line: LNCAP) [2]
PD-0325901 + Sorafenib DC9BP9V Sorafenib Prostate carcinoma (Cell Line: VCAP) [2]
PD-0325901 + MK-2206 DC7UTM2 MK-2206 Adenocarcinoma (Cell Line: OVCAR3) [2]
PD-0325901 + MK-2206 DCFWLG9 MK-2206 Adenocarcinoma (Cell Line: A427) [2]
PD-0325901 + MK-2206 DCLHADZ MK-2206 Adenocarcinoma (Cell Line: NCIH1650) [2]
PD-0325901 + MK-2206 DCDI39N MK-2206 Adenocarcinoma (Cell Line: NCIH2122) [2]
PD-0325901 + MK-2206 DCNG2LD MK-2206 Adenocarcinoma (Cell Line: NCIH520) [2]
PD-0325901 + MK-2206 DCLWN16 MK-2206 Adenocarcinoma (Cell Line: NCIH23) [2]
PD-0325901 + MK-2206 DCAMEBC MK-2206 Adenocarcinoma (Cell Line: COLO320DM) [2]
PD-0325901 + MK-2206 DCR6BA2 MK-2206 Adenocarcinoma (Cell Line: DLD1) [2]
PD-0325901 + MK-2206 DCH56PU MK-2206 Adenocarcinoma (Cell Line: HT29) [2]
PD-0325901 + MK-2206 DC4ZF58 MK-2206 Amelanotic melanoma (Cell Line: A2058) [2]
PD-0325901 + MK-2206 DCI0R4X MK-2206 Large cell lung carcinoma (Cell Line: NCI-H460) [2]
PD-0325901 + MK-2206 DCL7I0X MK-2206 Malignant melanoma (Cell Line: RPMI7951) [2]
PD-0325901 + MK-2206 DC8URF5 MK-2206 Malignant melanoma (Cell Line: UACC62) [2]
PD-0325901 + MK-2206 DCR3YSO MK-2206 Mesothelioma (Cell Line: MSTO) [2]
PD-0325901 + MK-2206 DCZ8EPL MK-2206 Non small cell carcinoma (Cell Line: SKMES1) [2]
PD-0325901 + MK-2206 DCYSXLR MK-2206 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [2]
PD-0325901 + MK-2206 DC4UPC5 MK-2206 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
PD-0325901 + MK-2206 DCJUY1E MK-2206 Prostate carcinoma (Cell Line: VCAP) [2]
PD-0325901 + MK-2206 DC5LJRR MK-2206 Prostate carcinoma (Cell Line: LNCAP) [2]
PD-0325901 + Vorinostat DCK6AU9 Vorinostat Adenocarcinoma (Cell Line: CAOV3) [2]
PD-0325901 + Vorinostat DCY0MJ5 Vorinostat Adenocarcinoma (Cell Line: OVCAR3) [2]
PD-0325901 + Vorinostat DCHD19T Vorinostat Adenocarcinoma (Cell Line: A427) [2]
PD-0325901 + Vorinostat DCZONCK Vorinostat Adenocarcinoma (Cell Line: NCIH1650) [2]
PD-0325901 + Vorinostat DCWOGKM Vorinostat Adenocarcinoma (Cell Line: NCIH2122) [2]
PD-0325901 + Vorinostat DC8H7BV Vorinostat Adenocarcinoma (Cell Line: NCIH23) [2]
PD-0325901 + Vorinostat DC4NGI9 Vorinostat Adenocarcinoma (Cell Line: NCIH520) [2]
PD-0325901 + Vorinostat DCVUXPJ Vorinostat Adenocarcinoma (Cell Line: COLO320DM) [2]
PD-0325901 + Vorinostat DC12CKB Vorinostat Adenocarcinoma (Cell Line: DLD1) [2]
PD-0325901 + Vorinostat DCHOPIQ Vorinostat Adenocarcinoma (Cell Line: HCT116) [2]
PD-0325901 + Vorinostat DCC3WC6 Vorinostat Adenocarcinoma (Cell Line: HT29) [2]
PD-0325901 + Vorinostat DCPSPI8 Vorinostat Adenocarcinoma (Cell Line: SW-620) [2]
PD-0325901 + Vorinostat DCZK2W6 Vorinostat Amelanotic melanoma (Cell Line: A2058) [2]
PD-0325901 + Vorinostat DCBTV1O Vorinostat Large cell lung carcinoma (Cell Line: NCI-H460) [2]
PD-0325901 + Vorinostat DC7TOCT Vorinostat Malignant melanoma (Cell Line: A375) [2]
PD-0325901 + Vorinostat DCMV03R Vorinostat Malignant melanoma (Cell Line: HT144) [2]
PD-0325901 + Vorinostat DCRCHCE Vorinostat Malignant melanoma (Cell Line: RPMI7951) [2]
PD-0325901 + Vorinostat DCE526N Vorinostat Malignant melanoma (Cell Line: SKMEL30) [2]
PD-0325901 + Vorinostat DCIG20P Vorinostat Mesothelioma (Cell Line: MSTO) [2]
PD-0325901 + Vorinostat DC1QEDH Vorinostat Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [2]
PD-0325901 + Vorinostat DCD4ZT4 Vorinostat Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
PD-0325901 + Vorinostat DCOBK02 Vorinostat Prostate carcinoma (Cell Line: LNCAP) [2]
PD-0325901 + Vorinostat DCRW4LT Vorinostat Prostate carcinoma (Cell Line: VCAP) [2]
PD-0325901 + Dasatinib DCY0Y4T Dasatinib Adenocarcinoma (Cell Line: CAOV3) [2]
PD-0325901 + Dasatinib DCCGBVS Dasatinib Adenocarcinoma (Cell Line: OVCAR3) [2]
PD-0325901 + Dasatinib DCUY5X6 Dasatinib Adenocarcinoma (Cell Line: A427) [2]
PD-0325901 + Dasatinib DCR365O Dasatinib Adenocarcinoma (Cell Line: NCIH1650) [2]
PD-0325901 + Dasatinib DCN6L5Z Dasatinib Adenocarcinoma (Cell Line: NCIH23) [2]
PD-0325901 + Dasatinib DCZDUH8 Dasatinib Adenocarcinoma (Cell Line: NCIH520) [2]
PD-0325901 + Dasatinib DCDLIUN Dasatinib Adenocarcinoma (Cell Line: DLD1) [2]
PD-0325901 + Dasatinib DC2KEXR Dasatinib Adenocarcinoma (Cell Line: HT29) [2]
PD-0325901 + Dasatinib DCPI7BV Dasatinib Adenocarcinoma (Cell Line: SW-620) [2]
PD-0325901 + Dasatinib DCYNB3X Dasatinib Amelanotic melanoma (Cell Line: A2058) [2]
PD-0325901 + Dasatinib DCDLC9Z Dasatinib Germ cell tumour (Cell Line: PA1) [2]
PD-0325901 + Dasatinib DCFZES4 Dasatinib Large cell lung carcinoma (Cell Line: NCI-H460) [2]
PD-0325901 + Dasatinib DCHD0AB Dasatinib Malignant melanoma (Cell Line: A375) [2]
PD-0325901 + Dasatinib DCXU44K Dasatinib Malignant melanoma (Cell Line: RPMI7951) [2]
PD-0325901 + Dasatinib DCMODXC Dasatinib Malignant melanoma (Cell Line: UACC62) [2]
PD-0325901 + Dasatinib DC9UHQM Dasatinib Mesothelioma (Cell Line: MSTO) [2]
PD-0325901 + Dasatinib DCQPPGN Dasatinib Non small cell carcinoma (Cell Line: SKMES1) [2]
PD-0325901 + Dasatinib DC0R5QP Dasatinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [2]
PD-0325901 + Dasatinib DC4UCVP Dasatinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
PD-0325901 + Dasatinib DC54J98 Dasatinib Prostate carcinoma (Cell Line: LNCAP) [2]
PD-0325901 + Dasatinib DC9UBBI Dasatinib Prostate carcinoma (Cell Line: VCAP) [2]
PF-04691502 + PD-0325901 DCQSAQM PF-04691502 Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [3]
PF-04691502 + PD-0325901 DCCF0AG PF-04691502 Primitive neuroectodermal tumor (Cell Line: TC-32) [3]
PMID28460551-Compound-2 + PD-0325901 DCDFPDF PMID28460551-Compound-2 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
PMID28460551-Compound-2 + PD-0325901 DCU80JT PMID28460551-Compound-2 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
PMID28460551-Compound-2 + PD-0325901 DC4MUM6 PMID28460551-Compound-2 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
PMID28460551-Compound-2 + PD-0325901 DC9O9JD PMID28460551-Compound-2 Breast carcinoma (Cell Line: ZR751) [4]
PMID28460551-Compound-2 + PD-0325901 DC7PUHK PMID28460551-Compound-2 Breast carcinoma (Cell Line: KPL1) [4]
PMID28460551-Compound-2 + PD-0325901 DC1HPL6 PMID28460551-Compound-2 Breast carcinoma (Cell Line: OCUBM) [4]
PMID28460551-Compound-2 + PD-0325901 DCP3PVI PMID28460551-Compound-2 Carcinoma (Cell Line: OV90) [4]
PMID28460551-Compound-2 + PD-0325901 DCQFRDT PMID28460551-Compound-2 Carcinoma (Cell Line: EFM192B) [4]
PMID28460551-Compound-2 + PD-0325901 DCRJ3EL PMID28460551-Compound-2 Carcinoma (Cell Line: MDAMB436) [4]
PMID28460551-Compound-2 + PD-0325901 DC45PX4 PMID28460551-Compound-2 Colon adenocarcinoma (Cell Line: LOVO) [4]
PMID28460551-Compound-2 + PD-0325901 DCB7DJV PMID28460551-Compound-2 Colon carcinoma (Cell Line: RKO) [4]
PMID28460551-Compound-2 + PD-0325901 DCBHNAG PMID28460551-Compound-2 Invasive ductal carcinoma (Cell Line: T-47D) [4]
PMID28460551-Compound-2 + PD-0325901 DCFPN01 PMID28460551-Compound-2 Rectal adenocarcinoma (Cell Line: SW837) [4]
PMID28460551-Compound-2 + PD-0325901 DCZ946N PMID28460551-Compound-2 Adenocarcinoma (Cell Line: OVCAR3) [2]
PMID28460551-Compound-2 + PD-0325901 DCJKNKQ PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH1650) [2]
PMID28460551-Compound-2 + PD-0325901 DCHGW9T PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH2122) [2]
PMID28460551-Compound-2 + PD-0325901 DC2EB35 PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH520) [2]
PMID28460551-Compound-2 + PD-0325901 DC4QD00 PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH23) [2]
PMID28460551-Compound-2 + PD-0325901 DCV6OLV PMID28460551-Compound-2 Adenocarcinoma (Cell Line: COLO320DM) [2]
PMID28460551-Compound-2 + PD-0325901 DCJZEEU PMID28460551-Compound-2 Adenocarcinoma (Cell Line: DLD1) [2]
PMID28460551-Compound-2 + PD-0325901 DCQO0SX PMID28460551-Compound-2 Adenocarcinoma (Cell Line: HCT116) [2]
PMID28460551-Compound-2 + PD-0325901 DCSU961 PMID28460551-Compound-2 Adenocarcinoma (Cell Line: HT29) [2]
PMID28460551-Compound-2 + PD-0325901 DCEEBYZ PMID28460551-Compound-2 Adenocarcinoma (Cell Line: SW-620) [2]
PMID28460551-Compound-2 + PD-0325901 DCXHD8X PMID28460551-Compound-2 Amelanotic melanoma (Cell Line: A2058) [2]
PMID28460551-Compound-2 + PD-0325901 DC6TGWS PMID28460551-Compound-2 Germ cell tumour (Cell Line: PA1) [2]
PMID28460551-Compound-2 + PD-0325901 DCN852K PMID28460551-Compound-2 Malignant melanoma (Cell Line: A375) [2]
PMID28460551-Compound-2 + PD-0325901 DCQNIUT PMID28460551-Compound-2 Malignant melanoma (Cell Line: HT144) [2]
PMID28460551-Compound-2 + PD-0325901 DCR5TJH PMID28460551-Compound-2 Malignant melanoma (Cell Line: RPMI7951) [2]
PMID28460551-Compound-2 + PD-0325901 DCMRYBD PMID28460551-Compound-2 Malignant melanoma (Cell Line: SKMEL30) [2]
PMID28460551-Compound-2 + PD-0325901 DCRUDNF PMID28460551-Compound-2 Malignant melanoma (Cell Line: UACC62) [2]
PMID28460551-Compound-2 + PD-0325901 DCMRECW PMID28460551-Compound-2 Mesothelioma (Cell Line: MSTO) [2]
PMID28460551-Compound-2 + PD-0325901 DCV04LU PMID28460551-Compound-2 Non small cell carcinoma (Cell Line: SKMES1) [2]
PMID28460551-Compound-2 + PD-0325901 DCE16QG PMID28460551-Compound-2 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [2]
PMID28460551-Compound-2 + PD-0325901 DCD217R PMID28460551-Compound-2 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
PMID28460551-Compound-2 + PD-0325901 DCEWLN0 PMID28460551-Compound-2 Prostate carcinoma (Cell Line: LNCAP) [2]
PMID28460551-Compound-2 + PD-0325901 DCSVFFU PMID28460551-Compound-2 Prostate carcinoma (Cell Line: VCAP) [2]
Pyrazinamide + PD-0325901 DCUMW4V Pyrazinamide Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
RAF265 + PD-0325901 DCBXCJM RAF265 Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [3]
Ribavirin-TP + PD-0325901 DCKSPP3 Ribavirin-TP Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
RTB101 + PD-0325901 DCFKO78 RTB101 Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [3]
RTB101 + PD-0325901 DCK7WYH RTB101 Primitive neuroectodermal tumor (Cell Line: TC-32) [3]
SCH 727965 + PD-0325901 DCRDCBN SCH 727965 Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [3]
SCH 727965 + PD-0325901 DCPJ3K3 SCH 727965 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
SCH 727965 + PD-0325901 DCIYVNH SCH 727965 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
SCH 727965 + PD-0325901 DC8NACR SCH 727965 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
SCH 727965 + PD-0325901 DC12B2O SCH 727965 Breast carcinoma (Cell Line: KPL1) [4]
SCH 727965 + PD-0325901 DCGQ8SN SCH 727965 Breast carcinoma (Cell Line: OCUBM) [4]
SCH 727965 + PD-0325901 DCGQFR4 SCH 727965 Carcinoma (Cell Line: EFM192B) [4]
SCH 727965 + PD-0325901 DCTFVFK SCH 727965 Carcinoma (Cell Line: MDAMB436) [4]
SCH 727965 + PD-0325901 DC0SVTA SCH 727965 Colon carcinoma (Cell Line: RKO) [4]
SCH 727965 + PD-0325901 DC3QN74 SCH 727965 Invasive ductal carcinoma (Cell Line: T-47D) [4]
SCH 727965 + PD-0325901 DC8MVO1 SCH 727965 Adenocarcinoma (Cell Line: CAOV3) [2]
SCH 727965 + PD-0325901 DCUKRQG SCH 727965 Adenocarcinoma (Cell Line: OVCAR3) [2]
SCH 727965 + PD-0325901 DC3QC57 SCH 727965 Adenocarcinoma (Cell Line: A427) [2]
SCH 727965 + PD-0325901 DCE4M13 SCH 727965 Adenocarcinoma (Cell Line: NCIH23) [2]
SCH 727965 + PD-0325901 DCQ41XZ SCH 727965 Adenocarcinoma (Cell Line: NCIH520) [2]
SCH 727965 + PD-0325901 DCEXRB4 SCH 727965 Adenocarcinoma (Cell Line: COLO320DM) [2]
SCH 727965 + PD-0325901 DCJ4RB5 SCH 727965 Adenocarcinoma (Cell Line: DLD1) [2]
SCH 727965 + PD-0325901 DCQAE80 SCH 727965 Adenocarcinoma (Cell Line: HCT116) [2]
SCH 727965 + PD-0325901 DCFJOD3 SCH 727965 Adenocarcinoma (Cell Line: HT29) [2]
SCH 727965 + PD-0325901 DCA0Z42 SCH 727965 Amelanotic melanoma (Cell Line: A2058) [2]
SCH 727965 + PD-0325901 DC3HLFN SCH 727965 Germ cell tumour (Cell Line: PA1) [2]
SCH 727965 + PD-0325901 DC9NLCP SCH 727965 Large cell lung carcinoma (Cell Line: NCI-H460) [2]
SCH 727965 + PD-0325901 DCZYOQU SCH 727965 Malignant melanoma (Cell Line: A375) [2]
SCH 727965 + PD-0325901 DC5DGWE SCH 727965 Malignant melanoma (Cell Line: HT144) [2]
SCH 727965 + PD-0325901 DCJ0NVY SCH 727965 Malignant melanoma (Cell Line: RPMI7951) [2]
SCH 727965 + PD-0325901 DC1LSTR SCH 727965 Malignant melanoma (Cell Line: SKMEL30) [2]
SCH 727965 + PD-0325901 DC8GWJW SCH 727965 Malignant melanoma (Cell Line: UACC62) [2]
SCH 727965 + PD-0325901 DCFHDAU SCH 727965 Mesothelioma (Cell Line: MSTO) [2]
SCH 727965 + PD-0325901 DCOF3G0 SCH 727965 Non small cell carcinoma (Cell Line: SKMES1) [2]
SCH 727965 + PD-0325901 DCLHZK0 SCH 727965 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [2]
SCH 727965 + PD-0325901 DCZHNC1 SCH 727965 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
SCH 727965 + PD-0325901 DCU9Q32 SCH 727965 Prostate carcinoma (Cell Line: VCAP) [2]
SNS-032 + PD-0325901 DC8JPE8 SNS-032 Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [3]
Taxol + PD-0325901 DCUOD8R Taxol Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Taxol + PD-0325901 DC7H8SQ Taxol Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Taxol + PD-0325901 DC8TCXZ Taxol Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Taxol + PD-0325901 DCSZTH2 Taxol Breast carcinoma (Cell Line: ZR751) [4]
Taxol + PD-0325901 DCVU9VW Taxol Breast carcinoma (Cell Line: OCUBM) [4]
Taxol + PD-0325901 DCZIBKS Taxol Carcinoma (Cell Line: OV90) [4]
Taxol + PD-0325901 DCVGPO1 Taxol Carcinoma (Cell Line: EFM192B) [4]
Taxol + PD-0325901 DC3QYU9 Taxol Carcinoma (Cell Line: MDAMB436) [4]
Taxol + PD-0325901 DCX4YRG Taxol Colon adenocarcinoma (Cell Line: LOVO) [4]
Taxol + PD-0325901 DCL4NAN Taxol Colon carcinoma (Cell Line: RKO) [4]
Taxol + PD-0325901 DCY0X4L Taxol Rectal adenocarcinoma (Cell Line: SW837) [4]
Taxol + PD-0325901 DC2YDC0 Taxol Adenocarcinoma (Cell Line: CAOV3) [2]
Taxol + PD-0325901 DCRGWPY Taxol Adenocarcinoma (Cell Line: OVCAR3) [2]
Taxol + PD-0325901 DCF5M8J Taxol Adenocarcinoma (Cell Line: A427) [2]
Taxol + PD-0325901 DCRYGZ8 Taxol Adenocarcinoma (Cell Line: NCIH23) [2]
Taxol + PD-0325901 DC2M4GP Taxol Adenocarcinoma (Cell Line: NCIH520) [2]
Taxol + PD-0325901 DCDRBWT Taxol Adenocarcinoma (Cell Line: COLO320DM) [2]
Taxol + PD-0325901 DC5ZR81 Taxol Adenocarcinoma (Cell Line: HCT116) [2]
Taxol + PD-0325901 DCE1B3E Taxol Adenocarcinoma (Cell Line: HT29) [2]
Taxol + PD-0325901 DC1ZQWU Taxol Adenocarcinoma (Cell Line: SW-620) [2]
Taxol + PD-0325901 DCPTQAX Taxol Amelanotic melanoma (Cell Line: A2058) [2]
Taxol + PD-0325901 DCF8UGP Taxol Germ cell tumour (Cell Line: PA1) [2]
Taxol + PD-0325901 DC5K6WQ Taxol Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Taxol + PD-0325901 DCA0AYL Taxol Malignant melanoma (Cell Line: A375) [2]
Taxol + PD-0325901 DCEHP32 Taxol Malignant melanoma (Cell Line: HT144) [2]
Taxol + PD-0325901 DC1AEP9 Taxol Malignant melanoma (Cell Line: RPMI7951) [2]
Taxol + PD-0325901 DCH9330 Taxol Malignant melanoma (Cell Line: SKMEL30) [2]
Taxol + PD-0325901 DCTN1G3 Taxol Mesothelioma (Cell Line: MSTO) [2]
Taxol + PD-0325901 DCJSIOH Taxol Non small cell carcinoma (Cell Line: SKMES1) [2]
Taxol + PD-0325901 DCD2HJL Taxol Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [2]
Taxol + PD-0325901 DCSPW4C Taxol Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
Taxol + PD-0325901 DC7KBLO Taxol Prostate carcinoma (Cell Line: VCAP) [2]
Topotecan + PD-0325901 DCW2QXV Topotecan Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Topotecan + PD-0325901 DCK95OC Topotecan Breast carcinoma (Cell Line: OCUBM) [4]
Topotecan + PD-0325901 DCFKX6L Topotecan Carcinoma (Cell Line: EFM192B) [4]
Topotecan + PD-0325901 DC21YB4 Topotecan Carcinoma (Cell Line: MDAMB436) [4]
Topotecan + PD-0325901 DCQH694 Topotecan Colon adenocarcinoma (Cell Line: LOVO) [4]
Topotecan + PD-0325901 DCL9DWF Topotecan Colon carcinoma (Cell Line: RKO) [4]
Topotecan + PD-0325901 DCYVPIH Topotecan Invasive ductal carcinoma (Cell Line: T-47D) [4]
Topotecan + PD-0325901 DCT6GKK Topotecan Adenocarcinoma (Cell Line: CAOV3) [2]
Topotecan + PD-0325901 DCJQZ42 Topotecan Adenocarcinoma (Cell Line: A427) [2]
Topotecan + PD-0325901 DC32I62 Topotecan Adenocarcinoma (Cell Line: NCIH2122) [2]
Topotecan + PD-0325901 DCBPP1W Topotecan Adenocarcinoma (Cell Line: NCIH520) [2]
Topotecan + PD-0325901 DCFACZZ Topotecan Adenocarcinoma (Cell Line: COLO320DM) [2]
Topotecan + PD-0325901 DC2PNT8 Topotecan Adenocarcinoma (Cell Line: DLD1) [2]
Topotecan + PD-0325901 DCLQDZE Topotecan Adenocarcinoma (Cell Line: HCT116) [2]
Topotecan + PD-0325901 DCN6XJ7 Topotecan Adenocarcinoma (Cell Line: HT29) [2]
Topotecan + PD-0325901 DCRV22A Topotecan Adenocarcinoma (Cell Line: SW-620) [2]
Topotecan + PD-0325901 DCQAYUQ Topotecan Amelanotic melanoma (Cell Line: A2058) [2]
Topotecan + PD-0325901 DCOFR51 Topotecan Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [2]
Topotecan + PD-0325901 DC5RN2I Topotecan Germ cell tumour (Cell Line: PA1) [2]
Topotecan + PD-0325901 DCKTDYR Topotecan Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Topotecan + PD-0325901 DCELR9H Topotecan Malignant melanoma (Cell Line: A375) [2]
Topotecan + PD-0325901 DCTYW79 Topotecan Malignant melanoma (Cell Line: HT144) [2]
Topotecan + PD-0325901 DCO69YY Topotecan Malignant melanoma (Cell Line: RPMI7951) [2]
Topotecan + PD-0325901 DCZ59ZJ Topotecan Malignant melanoma (Cell Line: SKMEL30) [2]
Topotecan + PD-0325901 DCJY6CJ Topotecan Malignant melanoma (Cell Line: UACC62) [2]
Topotecan + PD-0325901 DCELTWO Topotecan Mesothelioma (Cell Line: MSTO) [2]
Topotecan + PD-0325901 DC1GPD7 Topotecan Non small cell carcinoma (Cell Line: SKMES1) [2]
Topotecan + PD-0325901 DCBQYW1 Topotecan Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [2]
Topotecan + PD-0325901 DC4XMU3 Topotecan Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
Topotecan + PD-0325901 DCO3BOQ Topotecan Prostate carcinoma (Cell Line: LNCAP) [2]
Topotecan + PD-0325901 DCDPZM0 Topotecan Prostate carcinoma (Cell Line: VCAP) [2]
Tosyl-l-arginine methyl ester + PD-0325901 DCIJZF9 Tosyl-l-arginine methyl ester Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
Venglustat + PD-0325901 DCM5LVP Venglustat Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
Vinblastine + PD-0325901 DCBESFT Vinblastine Adenocarcinoma (Cell Line: CAOV3) [3]
Vinblastine + PD-0325901 DC7XOOF Vinblastine Adenocarcinoma (Cell Line: OVCAR3) [3]
Vinblastine + PD-0325901 DC2MLE4 Vinblastine Adenocarcinoma (Cell Line: NCIH1650) [3]
Vinblastine + PD-0325901 DCIR7LK Vinblastine Adenocarcinoma (Cell Line: NCIH2122) [3]
Vinblastine + PD-0325901 DCXLDKP Vinblastine Adenocarcinoma (Cell Line: NCIH23) [3]
Vinblastine + PD-0325901 DC5FHXU Vinblastine Adenocarcinoma (Cell Line: NCIH520) [3]
Vinblastine + PD-0325901 DCA8F80 Vinblastine Adenocarcinoma (Cell Line: COLO320DM) [3]
Vinblastine + PD-0325901 DC14BLX Vinblastine Adenocarcinoma (Cell Line: HT29) [3]
Vinblastine + PD-0325901 DC48269 Vinblastine Amelanotic melanoma (Cell Line: A2058) [3]
Vinblastine + PD-0325901 DC7DTDF Vinblastine Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Vinblastine + PD-0325901 DCU4JVU Vinblastine Germ cell tumour (Cell Line: PA1) [3]
Vinblastine + PD-0325901 DCI8O1C Vinblastine Malignant melanoma (Cell Line: A375) [3]
Vinblastine + PD-0325901 DC2SGMD Vinblastine Malignant melanoma (Cell Line: HT144) [3]
Vinblastine + PD-0325901 DCGJFPT Vinblastine Malignant melanoma (Cell Line: RPMI7951) [3]
Vinblastine + PD-0325901 DC35XVA Vinblastine Malignant melanoma (Cell Line: UACC62) [3]
Vinblastine + PD-0325901 DCJ8B3X Vinblastine Mesothelioma (Cell Line: MSTO) [3]
Vinblastine + PD-0325901 DC0HUZ5 Vinblastine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Vinblastine + PD-0325901 DCRJ392 Vinblastine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Vinblastine + PD-0325901 DCA1TB8 Vinblastine Prostate carcinoma (Cell Line: VCAP) [3]
Vinblastine + PD-0325901 DCP8CC7 Vinblastine Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Vinblastine + PD-0325901 DC35LLF Vinblastine Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Vinblastine + PD-0325901 DCNS3VG Vinblastine Breast carcinoma (Cell Line: KPL1) [4]
Vinblastine + PD-0325901 DCB3I1Z Vinblastine Breast carcinoma (Cell Line: OCUBM) [4]
Vinblastine + PD-0325901 DC0S9TM Vinblastine Carcinoma (Cell Line: OV90) [4]
Vinblastine + PD-0325901 DC6F15U Vinblastine Carcinoma (Cell Line: MDAMB436) [4]
Vinblastine + PD-0325901 DCCP1LE Vinblastine Colon carcinoma (Cell Line: RKO) [4]
Vinblastine + PD-0325901 DC3VU2V Vinblastine Rectal adenocarcinoma (Cell Line: SW837) [4]
Vinorelbine + PD-0325901 DCFPPX1 Vinorelbine Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Vinorelbine + PD-0325901 DC9MINX Vinorelbine Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Vinorelbine + PD-0325901 DC4AAI1 Vinorelbine Breast carcinoma (Cell Line: KPL1) [4]
Vinorelbine + PD-0325901 DCS5WSN Vinorelbine Breast carcinoma (Cell Line: OCUBM) [4]
Vinorelbine + PD-0325901 DCVWMN4 Vinorelbine Carcinoma (Cell Line: OV90) [4]
Vinorelbine + PD-0325901 DCFKTH4 Vinorelbine Carcinoma (Cell Line: EFM192B) [4]
Vinorelbine + PD-0325901 DCDLWTC Vinorelbine Colon adenocarcinoma (Cell Line: LOVO) [4]
Vinorelbine + PD-0325901 DCTOWK5 Vinorelbine Colon carcinoma (Cell Line: RKO) [4]
Vinorelbine + PD-0325901 DCTQMAM Vinorelbine Rectal adenocarcinoma (Cell Line: SW837) [4]
Vinorelbine + PD-0325901 DC06M2V Vinorelbine Adenocarcinoma (Cell Line: OVCAR3) [2]
Vinorelbine + PD-0325901 DC9DPI8 Vinorelbine Adenocarcinoma (Cell Line: A427) [2]
Vinorelbine + PD-0325901 DCJSMXA Vinorelbine Adenocarcinoma (Cell Line: NCIH1650) [2]
Vinorelbine + PD-0325901 DCPR95Y Vinorelbine Adenocarcinoma (Cell Line: NCIH520) [2]
Vinorelbine + PD-0325901 DC4UAKO Vinorelbine Adenocarcinoma (Cell Line: COLO320DM) [2]
Vinorelbine + PD-0325901 DCPD02U Vinorelbine Adenocarcinoma (Cell Line: HCT116) [2]
Vinorelbine + PD-0325901 DCDW8ZZ Vinorelbine Adenocarcinoma (Cell Line: HT29) [2]
Vinorelbine + PD-0325901 DCFV2QL Vinorelbine Adenocarcinoma (Cell Line: SW-620) [2]
Vinorelbine + PD-0325901 DC425AY Vinorelbine Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [2]
Vinorelbine + PD-0325901 DCPCD2U Vinorelbine Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Vinorelbine + PD-0325901 DCPYYQ4 Vinorelbine Malignant melanoma (Cell Line: SKMEL30) [2]
Vinorelbine + PD-0325901 DCGCOBV Vinorelbine Mesothelioma (Cell Line: MSTO) [2]
Vinorelbine + PD-0325901 DCLX6MU Vinorelbine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [2]
Vinorelbine + PD-0325901 DC9NEPT Vinorelbine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
Vinorelbine + PD-0325901 DC0UMN9 Vinorelbine Prostate carcinoma (Cell Line: LNCAP) [2]
Vinorelbine + PD-0325901 DCHOIT6 Vinorelbine Prostate carcinoma (Cell Line: VCAP) [2]
Ym155 + PD-0325901 DCL0K7K Ym155 Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [3]
------------------------------------------------------------------------------------
⏷ Show the Full List of 1122 DrugCom(s)
2 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
PD-0325901 + PF-05212384 DCHCXN7 PF-05212384 Advanced Cancer [5]
PD-0325901 + Docetaxel DCS8A41 Docetaxel Colorectal Cancer [6]
------------------------------------------------------------------------------------

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7935).
2 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
3 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
4 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
5 ClinicalTrials.gov (NCT01347866) Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer
6 ClinicalTrials.gov (NCT02039336) Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC